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Abstract
Clinical interest in the human gut microbiota has increased considerably, 
because of the increasing number of studies linking the human intestinal 
microbiota and microbiome to an ever increasing number of non-communicable 
diseases. Many attempts at modulating the gut microbiota have been made 
using probiotics and prebiotics. However, there are other avenues that are still 
little explored from a clinical point of view that appear promising to obtain 
modifications of the microbial ecology and biological activities connected to 
the microbiome. This chapter summarizes all in vitro, in vivo and clinical studies 
demonstrating the possibility to positively modulate the intestinal microbiota 
by using probiotics, foods (and prebiotics), essential oils, fungus and officinal 
plants. For the future, clinical studies investigating the ability to modify the 
intestinal microbiota especially by using foods, officinal and aromatic plants or 
their extracts are required. More knowledge in this field is likely to be of clinical 
benefit since modulation of the microbiome might support the therapy of most 
non-communicable diseases in the future.
Keywords: microbiota, microbiome, probiotics, essential oils, phytotherapy
1. The pivotal role of gut microorganisms in human health
Our knowledge of the relationship between human beings and the microor-
ganisms we harbor in our gut has greatly increased in the past years, even if we 
are still far from having understood all their functions. We no longer consider 
these living entities as simply commensal, and we start to realize that humans are 
“super organisms” governed also by the microorganisms living inside us. There are 
approximately 100 trillion cells in the human body, and more than 90% of them 
are microbes. They make up the human microbiota, consisting of bacteria, fungi 
and even viruses, mainly located in the intestine where they are referred to as the 
intestinal microbiota.
The terms currently employed in this field are the following:
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Microbiota, which refers to the communities of living microorganisms residing 
in a defined ecological niche.
Microbiome, which indicates the whole of the microorganisms, i.e. their genes 
(genome), their proteins (proteome) and their metabolites (metabolome) (even if 
the terms microbiota and microbiome are often used interchangeably).
Metagenomics, which is the analysis usually performed by next-generation 
sequencing techniques, of the genetic material of microorganisms obtained from a 
sample of the environment that is being studied, such as for example feces for the 
profiling of the fecal microbiota.
Dysbiosis, which is an alteration in the microbiota structure (as opposed to 
eubiosis), with negative implications for microbial metabolism and host physiology.
The first consideration that we have to do is that the microbial ecosystem of the 
intestine called gut microbiota, is one of the most dense communities that we know, 
surpassing for complexity those present in soil, subsoil and also oceans [1].
The second consideration is that the microbiota does not represent an inheri-
tance dependent on our species or genes, but rather an environmental inheritance, 
mainly due to the type of environment to which we have been exposed in the first 
3–4 years of our life [2]. This also implies that we can act during life with the aim of 
improving our microbiota (Figure 1).
The last one is that our gut microbiota and microbiome are strictly connected 
with our state of health or illness and, together with genetics and environment, 
certainly represent a discriminating point in predisposing us to the onset of some 
particular diseases rather than that of others. The gut microbiota is closely related to 
our metabolic balance as well as to the development and functioning of our immune 
system, as studies on germ-free animals have clearly shown. It is also closely con-
nected with the intestinal and systemic endocrine system, and indirectly with the 
central nervous system, via the enteric nervous system, within what is commonly 
called the gut-brain axis [3].
These considerations must not make us think of the microbiota and microbiome 
as something fixed and stable in the course of our life. The aging of our organism 
physiologically leads to a change in the gut microbiota with a decrease in some 
specific populations, such as the short-chain fatty acid (SCFA)-producing families 
Lachnospiraceae and Ruminococcaceae, and an increase in potential or opportunistic 
pathogens, as enterobacteria. Aging is also accompanied by an increase in low-grade, 
chronic inflammation. This so-called “Inflammaging” impacts gut integrity and can 
be causally linked to age-related changes in the microbiota [4]. Inflammation and 
dysbiosis are always closely connected to each other and inevitably end up entering 
Figure 1. 
The microbiota present in human gut is strictly connected with the whole organism state of health or illness. 
Major factors capable of modulating the gut microbiota in adults are represented in this picture.
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into loops of which it is difficult or impossible to establish which of the two is the 
cause and which the consequence. Aging is also accompanied by increased intestinal 
permeability, impaired digestion, and disrupted nutrient absorption, each of which 
exhibits bidirectional interactions with the gut microbiome [5].
In addition to the physiological and irreversible increase in our biological age, 
there are other conditions that have a decisive impact on the composition and 
function of the intestinal microbiota. The first for importance and for the daily 
life with which it is implemented, is certainly our diet, which can cause, as we will 
see in the next paragraph, positive or negative changes in the microbiota. Another, 
often overlooked, condition is our lifestyle. Smoking and alcohol, for example, can 
negatively alter the microbiome [6], while regular physical activity seems to be 
capable of significantly improving it [7].
Finally, as we will analyze in the following paragraphs, there are many different 
pathologies, and consequent therapies, that can alter our intestinal microbiota, 
sometimes irreversibly. The most illuminating example concerns the transmissible 
pathologies of bacterial origin, encountered at an early age. The antibiotic therapies 
that often become necessary can, in the first 3 years of life, irreversibly alter the 
developmental trajectory of the intestinal microbiota leading, in the adult age, to 
a microbiota substantially different from that which would have developed in the 
absence of broad-spectrum antibiotic therapies [8]. On the contrary, antibiotic 
therapy in adults only reversibly alters the intestinal microbiota, which returns 
exactly to the starting point after the end of the therapy [9] Other intestinal 
pathogens, such as Campylobacter jejuni, can cause dysbiosis that persists even after 
the infection has been resolved, as it happens for example in the case of patients 
who develop post-infectious Irritable Bowel Syndrome (IBS) after enteritis caused 
by this bacterium [10].
However, we must not think that the pathologies correlated to alterations of 
the microbiota are essentially limited to the gastro-intestinal or metabolic ones. 
In recent years, many studies have linked alterations in the gut microbiome with 
a plethora of various diseases, including the neurodegenerative ones, such as 
Alzheimer’s or Parkinson’s [11]. Despite our limited mechanistic understanding of 
how the microbiota can predispose to neurodegenerative diseases, efforts to manip-
ulate the microbiota through fecal microbiota transplantation, probiotic treatment, 
or other nutritional strategies, highlight the potential for microbial improvement 
in successfully preventing or decreasing the symptoms of these diseases, at least in 
laboratory animals [12]. It is therefore not surprising that some studies today are 
explicitly aimed at microbiome-targeted interventions for the prevention or treat-
ment of neurodegenerative diseases.
To conclude this paragraph of premises, we can state that while conventional 
medicine aimed at maximum specialization, with branches such as organ and 
cellular medicine, on the other side of the pond the role of the intestinal microbiota 
has gradually assumed more and more importance, to remind us that our “super 
organism” is unique and that alterations of our gut microbial component, that 
is not even part of our cellular pool, can have a broad-spectrum negative impact 
on many if not all the organs and apparatuses that make up our organism. The 
microbiota well represents the complex relationships that exist between our health 
and the environment in which we are born and spend the first years of our life. A 
compromised environment, due to excessive sterilization or pollution, certainly has 
a strong impact on the structure of our microbiota in adulthood and, consequently, 
also on our state of health and well-being. Although fecal microbiota transplanta-
tion has opened new frontiers on the prevention and treatment of many patholo-
gies, it is indisputably true that this community of microorganisms represents a 
central node in the functioning of all our organs and systems, and at the same time 
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it denotes a fundamental point of interaction between us and the environment in 
which we spend our lives.
2. Intestinal dysbiosis, immune system and related human pathologies
Intestinal dysbiosis is mainly characterized by lower bacterial diversity and it 
is often associated with an increase in bacterial species with pathogenic potential 
(i.e., pathobionts) to the detriment of health-associated symbiotic commensals. 
Dysbiosis has been associated with several human pathologies, as demonstrated by 
several preclinical and clinical studies (Figure 2). Despite this evidence, it is almost 
never clear whether dysbiosis is a consequence of these diseases or if it is directly 
involved in their pathogenesis. Nevertheless, it is widely accepted that an imbalance 
of the intestinal microbiota may impact on diseases development and their clini-
cal outcome. A consequence of intestinal dysbiosis is the loss of the barrier effect, 
followed by an impairment of the gut-associated immune system function. Mucosal 
barrier disruption leads to the release of pathogen-associated molecular patterns 
(PAMPs), triggers epithelial release of damage-associated molecular patterns 
(DAMPs), and finally causes the release of bacterial lipopolysaccharides (LPS) into 
the systemic circulation (metabolic endotoxaemia) [13]. The consequent activa-
tion of inflammatory pathways links intestinal dysbiosis to chronic inflammatory 
pathologies, autoimmune disorders and also cancer.
Moreover, together with the dysbiosis-related inflammation, the depletion 
of specific bacterial taxa involved in endocrine signaling may directly affect the 
function of different organs, and for these reasons dysbiosis has also been linked to 
metabolic, endocrine (e.g. thyroid-related) and also psychiatric disorders [14].
2.1 Dysbiosis in gastrointestinal disorders
A marked dysbiosis has been found to be associated with the main intestinal 
disorders, such as Inflammatory Bowel Diseases (IBD), Irritable Bowel Syndrome 
(IBS) and coeliac disease (CD). IBD are chronic inflammatory disorders char-
acterized by the chronic activation of the immune system with an unbalanced 
production of inflammatory cytokines. Despite the pathogenesis of these diseases 
is unclear, there is evidence that, other than genetic and environmental factors, 
Figure 2. 
Food, lifestyle, xenobiotics and aging are the main causes that can lead to dysbiosis and consequently to an 
alteration of the intestinal barrier function. These two conditions are linked immune system impairment and 
to the possible onset of many pathologies. PAMPs, pathogen-associated molecular patterns; DAMPs damage-
associated molecular patterns (DAMPs).
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an abnormal immune response against the microbial component of the gut may 
be involved in inflammation development and maintenance. It has been sup-
posed that dysbiosis could trigger an aberrant activation of immune system in 
IBD patients, resulting in an unbalanced inflammatory cytokine production. 
In particular, compared to controls, the anti-inflammatory butyrate-producing 
species Faecalibacterium prausnitzii has been found to be reduced in both Crohn’s 
disease and ulcerative colitis patients, with the latter also showing an increase in 
Clostridium perfringens and a decrease of Eubacterium rectale. Overall, members 
of the Proteobacteria phylum, such as Enterobacteriaceae, including Escherichia 
coli, are increased in patients with IBD compared to healthy individuals [15]. Also 
pouchitis, an inflammation involving the transition tissue (pouch) in patients 
with IBD who underwent proctocolectomy, is characterized by severe chronic 
dysbiosis [16, 17]. The involvement of the gut microbial component in these 
disorders is also supported by the efficacy of antibiotic therapy and probiot-
ics, which are often used in order to manage inflammatory flares, especially in 
pouchitis, despite specific bacterial pathogens have never been found in these 
patients [18].
IBS is characterized by recurrent abdominal pain associated with a change in the 
bowel habits. IBS patients are divided into four subtypes: diarrhea-predominant 
(IBS-D), constipation-predominant (IBS-C), mixed diarrhea and constipation 
(IBS-M), and patients with non classifiable IBS symptoms (IBS-U) [19]. These 
patients are characterized by a lower microbial diversity compared to the healthy 
population, and also by increased proportions of Proteobacteria and Firmicutes 
members, such as Veillonella, Lactobacillus and Ruminococcus, and decreased relative 
abundance of Bifidobacterium, Faecalibacterium, Erysipelotrichaceae, and methano-
gens. Despite the etiology of this disease is unknown, the role of the gut microbiota 
component is supported by experiments on animals with induced dysbiosis, which 
showed abnormal intestinal behaviors similar to those typical of IBS patients [20]. 
Moreover, a number of studies have shown some improvement in IBS symptoms 
with antibiotic therapy, including rifaximin [21].
Coeliac disease (CD) is a well-characterized gut autoimmune disorder triggered 
by the interaction between the gut-associated lymphoid immune system and the 
undigested gluten peptides that translocate through the epithelial barrier into the 
lamina propria. About 30% of the world population is genetically predisposed to 
develop CD, but only a small amount (about 1% in developed countries) develops 
the disease, so a multifactorial etiology is supposed for this disorder. CD patient 
microbiota is characterized by an increased relative abundance of Bacteroides, 
Prevotella and Escherichia, and reduced amounts of bifidobacteria and lactobacilli. It 
has been supposed that this dysbiotic profile may contribute to the disease develop-
ment by influencing the gluten peptide digestion, by stimulating dendritic cells and 
Treg lymphocytes and also by increasing intestinal permeability [22].
2.2 Dysbiosis in thyroid and autoimmune disorders
There is rising evidence that the intestinal microbiota compositional structure 
may impact on thyroid function, since microbial components can regulate iodine, 
selenium, iron and zinc uptake, and also enterohepatic cycling of thyroid hormones. 
Moreover, the microbiota may also impact on the bioavailability and metabolism of 
L-thyroxine and the anti-hyperthyroid drug propylthiouracil (PTU) [23]. The gut 
microbiota influences the synthesis of neurotransmitters, such as dopamine, which 
can inhibit thyroid-stimulating hormone (TSH) and modulate hypothalamus-pitu-
ary axis. It is therefore reasonable to affirm that intestinal dysbiosis may contribute 
to the abnormal immune activation in Hashimoto’s thyroiditis (HT) [24] but also 
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in Grave’s disease (GD), which is the second leading autoimmune thyroid disease. 
Studies on animals showed that microbiota transplant may increase the susceptibil-
ity to HT in rats. A proposed mechanism of action, is that Lactobacillus spp. and 
Bifidobacterium spp. may affect the synthesis of antibodies cross-reacting with 
thyreoperoxidase and thyroglobulin [25]. Notably, it has also been supposed that 
dysbiosis in HT patients may affect Treg cells modulation, a common feature shared 
with CD, which is often associated with thyroid disorders [26].
HT and GD evolve, respectively, in hypothyroidism and hyperthyroidism, with 
two distinct immunological patterns. HT is characterized by antibodies against 
thyreoperoxidase and thyroglobulin while GD is characterized by the presence of 
antibodies against TSH receptor. Nevertheless, in both disorders, anti-gliadin, anti-
transglutaminase and anti-Saccharomyces cerevisiae antibodies have been detected, 
and both disorders are characterized by intestinal dysbiosis. A study conducted on 28 
HT patients and 16 healthy controls showed an increase in the proportions of Blautia, 
Roseburia, Ruminococcus, Romboutsia, Dorea, Fusicatenibacter and Eubacterium group 
genera, and a decrease in Fecalibacterium, Bacteroides, Prevotella and Lachnoclostridium 
in HT [24]. Another study on 27 GD patients showed an increase of Prevotellaceae 
and Pasteurellaceae and a decreased amount of Enterobacteriaceae, Veillonellaceae and 
Rikenellaceae compared to healthy subjects [27].
2.3 Dysbiosis in metabolic disorders
Obesity, type-2 diabetes, metabolic syndrome and nonalcoholic fatty liver 
disease (NAFLD) are all metabolic disorders that manifest in comorbidity, and lead 
to an exacerbation of atherosclerosis and cardiovascular diseases [28]. These disor-
ders are characterized by different microbial signatures, which may contribute to 
their chronicization. The intestinal microbiota has an active role in regulating host 
metabolism, indeed experiments on mice showed that conventionally raised mice 
had more total body fat than mice raised in germ-free condition, and that a fecal 
transplant in these mice was able to restore nutrient adsorption, metabolic function 
and body fat [29].
In obese subjects, a lower bacterial richness was detected, along with a predomi-
nance of “pro-inflammatory” taxa, such as Ruminococcus gnavus and Bacteroides, 
over the “anti-inflammatory” species F. prausnitzii [30]. Microbiome analysis in 
type 2 diabetes patients showed an altered pattern enriched in membrane transport 
of sugars and branched-chain amino acid transport, while depleted in butyrate 
synthesis, with a decrease of Roseburia intestinalis and F. prausnitzii [31]. Moreover, 
fecal transplant from lean donors to patients with metabolic syndrome showed 
to ameliorate their insulin resistance condition [32]. There is also evidence that 
overgrowth of SCFA-producing bacteria is directly correlated to an improvement 
of glycemic control, through regulation of glucagon-like peptide 1 [33]. In NAFLD 
patients, a microbial signature characterized by higher relative abundance of 
proteobacteria was detected, moreover there is a correlation between the microbiota 
composition and the degree of liver fibrosis. Patients with an advanced liver fibrosis 
showed a further increase of proteobacteria, particularly E. coli, and a decrease of 
Firmicutes [34].
Intestinal dysbiosis has also been found in subjects with a high risk for cardio-
vascular diseases compared to subjects with low risk. In particular, some bacterial 
genera, such as Prevotella and Klebsiella, seem to correlate with hypertension 
[35] Fecal transplantation from patients with overrepresentation of these two 
genera to germ-free mice led to an increase of blood pressure in experimental 
animals [36].
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2.4 Dysbiosis in cancer
Intestinal microbiota disruption has been linked to the development of cancer, 
and different specific strains have been linked to the development of different 
tumors. In colorectal cancer (CRC) a particular strain of Fusobacterium nucleatum 
seems to be involved in CRC initiation and progression by activating different 
pathways leading to a rise of pro-inflammatory cytokines, such as IL-6, IL-8 and 
TNF-α, and to the development of an immunosuppressive microenvironment and 
also to the induction of chemoresistance to 5-fluorouracil [37].
In hepatocellular cancer, the translocation of gut microbiota and its products via 
the portal vein seems to be a condition able to trigger inflammation and chronic liver 
disease that predisposes patients to the development of cancer [38].
Leukemia patients showed a marked dysbiosis. In acute lymphoblastic leukemia 
(ALL) patients, a lower microbial diversity has been found, along with an enrich-
ment in Enterococcaceae, Porphyromonadaceae and other Bacteroidetes members, 
and a depletion in Blautia, Erysipelotrichales, Lachnospiraceae and Clostridiales 
members. In acute myeloid leukemia (AML), the abundance of Staphylococcaceae 
and Streptococcaceae represents a typical signature [39]. In lung cancer, a dysbiosis 
characterized by increased relative abundance in Enterococcus, Bacteroides and 
Fusobacterium, and a depletion in Bifidobacterium and other Actinobacteria compo-
nents, Dialister, Enterobacter, Escherichia-Shigella, Fecalibacterium and Kluyvera has 
been detected [40].
In non-small cell lung cancer (NSCLC) patients, a depletion of butyrate produc-
ers such as F. prausnitzii, Clostridium leptum, Clostridial cluster I, Ruminococcus 
spp., Clostridial cluster XIVa, and Roseburia spp., has been described [41, 42].
2.5 Psychiatric disorders
There is evidence that psychiatric disorders such as schizophrenia (SCZ), autism 
spectrum disorders, mood disorders, and anxiety are linked to gut inflammation 
and that inflammatory status could be sustained by gut microbiota eubiosis break-
down [43]. Epidemiological studies link autoimmune and atopic disorders such as 
systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and ankylosing 
spondylitis (AS) to affective, personality, and neurotic disorders [44].
A study conducted on Danish population demonstrated that individuals with 
SCZ have a 50% lifetime prevalence of autoimmune disorders. On the other hand, 
given a history of autoimmune disorders, the relative risk for SCZ increased by 
45% [45].
An association between SCZ and RA, autoimmune thyroiditis, type 1 diabetes 
mellitus (T1DM), SLE, Guillain-Barre´ syndrome, psoriasis, multiple sclerosis 
(MS) and autoimmune hepatitis has been described [46]. Interestingly, all these 
diseases have been associated with CD and non–celiac gluten sensitivity, with a 
higher prevalence of immunological markers of CD among these patients [47].
Clinical and animal preclinical studies support the relationship between gut 
inflammation and mental disorders. Indeed, high levels of pro-inflammatory 
circulating cytokines such as IL-1b, IL-6, and TNF-α, have been found in patients 
suffering from SCZ. Moreover, immunomodulatory drugs have been used to effec-
tively treat psychosis [43]. In patients with a high risk of psychosis, Clostridiales, 
Lactobacillales and Bacteroidales were found to be significantly higher than in 
healthy controls [48].
It has been hypnotized that the excessive rise of SCFA synthesis could be one of 
the causes of microglia activation. Studies on SCZ patients showed heterogeneous 
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results on the microbiota dysbiosis so, despite such a dysbiosis was always con-
firmed in these patients, it is difficult to link specific taxa to this disorder [43]. 
Anyway, fecal transplantation from SCZ patients to germ-free mice resulted in the 
development of SCZ-like behaviors in receiving mice, providing final evidence 
of the gut microbiota involvement in SCZ. An unbalanced microbiota was also 
detected in bipolar disorders and autism spectrum disorders, to underline that our 
gut microbiome may contribute, probably with varying importance, to most mental 
and stress-related disorders [43].
2.6 Neurodegenerative disorders
The implication of gut microbiota in neurodegenerative disorders has been 
widely investigated. Several clinical studies in Parkinson’s disease (PD) patients 
showed modifications in the gut microbiota, characterized by a rise in the rela-
tive abundance of Bifidobacterium, Lactobacillus and Verrucomicrobiaceae, and a 
decrease in Blautia, Coprococcus and Prevotellaceae [49]. Interestingly, microbiota 
modifications are stable after the disease onset and some of these changes correlate 
with alterations in microbial metabolism of tryptophan and beta-glucuronide [50]. 
In addition to altered microbial metabolism, intestinal dysbiosis could be involved 
in PD development through immune-mediate pathways, since there is evidence 
that links GI inflammation to PD, maybe since inflammation may enhance alpha-
synuclein aggregation [49].
For what concerns Alzheimer’s disease (AD), animal experiments on mice with 
induced dysbiosis and on germ-free mice showed that microbiota manipulation can 
impact on disease severity and cognitive impairments. LPS seems to be involved 
in fibrillogenesis of β-Amiloid (Aβ), and some bacterial species, such as E. coli, 
Bacillus subtilis, Salmonella Typhimurium, Salmonella enterica, Mycobacterium 
tuberculosis, and Staphylococcus aureus may generate functional amyloid, contribut-
ing to the pathogenesis of AD through the accumulation of proteinaceous misfolded 
Aβ oligomers and fibrils [51].
3.  Probiotics for the modulation of human microbiota: Effectiveness and 
limits
Since the second half of the 19th century, with Metchnikoff ’s studies on the 
possibility of using lactic acid bacteria to decelerate the process of self-intoxication 
and infection by intestinal microbes [52] probiotics have been recognized as a 
tool to modulate the gut microbiota while conferring benefits to health. Their 
economic value was recognized shortly thereafter, and their global market is 
estimated to reach USD 69.3 billion by 2023 [https://www.marketsandmarkets.com/
PressReleases/probiotics.asp]. Nowadays, probiotics represent one of the most com-
monly consumed food supplements worldwide, being present in yogurt, cheese, 
ice cream, snacks and nutritional bars, breakfast cereals, infant formulas and more 
recently also added to cosmetic products. They are also marketed as lyophilized 
pills, and their consumption is widely supported by physicians, particularly gastro-
enterologists [53]. The administration of probiotics is indeed a more than feasible 
approach in clinical practice, compared for example to diet, despite its recognized 
role as a pivotal determinant of the structure and function of the gut microbiota, 
able to support homeostasis or vice versa to contribute to the susceptibility to disease 
[54], due to the sometimes modest effects of nutritional interventions and the dif-
ficult of enforcing and monitoring patient compliance. The mainstay of commercial 
supply is represented by Lactobacillus and Bifidobacterium species, along with E. 
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coli Nissle 1917, Streptococcus thermophilus and Saccharomyces boulardii, all with a 
long history of use, having Generally Recognized as Safe (GRAS) status in the US or 
being granted Qualified Presumption of Safety status by the European Food Safety 
Authority (EFSA). Being sourced from the gut or traditional fermented foods, they 
have been selected, in large part, for their technological properties, i.e. the ability to 
survive processing and to retain viability during the shelf-life of the product.
According to the International Scientific Association for Probiotics and 
Prebiotics consensus meeting in October 2013 [55], the framework “probiotics” 
must include microbial species that have been shown in properly controlled stud-
ies to confer health benefits. Probiotics are also new commensals and consortia 
that include defined strains from human samples, for which adequate evidence of 
safety and efficacy exists. On the other hand, live cultures, traditionally associated 
with fermented foods (with no evidence of health benefits), and undefined, fecal 
microbiota transplants must be kept outside this framework.
Probiotics may have several effects on the host, including certainly the modula-
tion of the gut microbiota but also the metabolism of lactose with improved diges-
tion or bile salts with various systemic effects, vitamin synthesis, direct and indirect 
pathogen antagonism, regulation of intestinal transit and alleviation of visceral 
pain, strengthening of the gut barrier, production of specific bioactives and neuro-
logical, immunological and endocrinological effects. As expected, some underly-
ing mechanisms are observed across taxonomic groups, such as the inhibition of 
potential enteropathogens or the production of useful metabolites or enzymes, 
while others, especially those at the extra-intestinal level, are more likely to be 
strain specific. These effects can be contact-dependent and/or mediated by surface 
molecules, e.g. lipoteichoic acid, peptidoglycan, cell surface proteins, exopolysac-
charide, pili or other appendages, or by secreted molecules, e.g. SCFAs and bacte-
riocins [56]. In light of this, it is not surprising that paraprobiotics and postbiotics 
have recently been proposed as an alternative with a longer shelf-life and enhanced 
safety, especially for compromised individuals, with the former being non-viable 
(intact or broken) microbial cells or crude cell extracts [57] and the latter microbial 
cell constituents and metabolites, which act as bioactive compounds with local and 
systemic effects [58].
With specific regard to the gut microbiota, probiotics may impact resident 
communities through at least three different mechanisms: trophic interactions (i.e. 
by stimulating growth through the supply of metabolites such as lactate, acetate or 
propionate, growth factors such as vitamins or exopolysaccharide, or other sub-
strates), a direct alteration of fitness, through a decrease in pH, niche competition 
or bacteriocin production, or an indirect one via host, through changes in the gut 
environment (i.e. by stimulating the production of mucins, increasing the levels of 
secretory IgAs and inducing the secretion of defensins, which represent the first 
line of defense of the intestinal epithelium against microbial invasion) [59]. As 
expected, while these effects may be relevant in the context of dysbiosis, i.e. when 
the blooming of potential opportunistic pathogens and/or the depletion of health-
associated (mainly SCFA-producing, oxidative stress-sensitive) taxa occur, there is 
no convincing evidence of consistent effects of probiotics on the gut microbiota of 
healthy subjects, i.e. on an eubiotic and resilient microbial ecosystem [60].
Among the main (although sometimes only suggested) prophylactic and thera-
peutic indications and claims of probiotics, we can certainly mention gastrointesti-
nal diseases, including the prevention or treatment of acute, antibiotic-associated 
and Clostridium difficile–associated diarrhea, and the amelioration of IBD and IBS 
[56]. Recent reviews have also cautiously suggested a beneficial role of probiotics 
in preterm infants, especially in terms of preventing necrotizing enterocolitis and 
reducing the risk of late-onset sepsis [61]. Bearing in mind that probiotics efficacy 
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is mostly strain-dependent and generalizations are highly inappropriate, moder-
ate to strong evidence is also available for the eradication of Helicobacter pylori 
and the prevention of adverse reactions to its therapy or post-surgical infections 
[62]. Contrasting data have instead been reported in the context of many other 
disorders, including for example respiratory infections and metabolic syndrome 
[63]. This confusing situation may arise from the heterogeneity of probiotic agents, 
dosage, duration and mode of administration, but also from other issues related to 
study design and reporting of results (not always transparent, easy to assess and 
rigorous), to the population (e.g. demographic characteristics) and environmental 
variables (e.g. habitual diet).
In this regard, the awareness that one size does not fit all is rapidly gaining 
ground. It is now a fact that distinct baseline features of the host (e.g. age and 
underlying medical condition) and its microbiota (taxa represented and functions 
performed), including varying environmental exposure (mainly diet), can actually 
lead to differing outcomes even with the same probiotic preparation. As discussed 
recently, this could for example be due to the fact that the individual configuration 
of the gut microbiota may be permissive or resistant to even transient colonization 
of probiotics [64]. Moreover, it has been shown that probiotics could even perturb 
rather than aid in the recovery process of the gut microbiota after antibiotic treat-
ment [9]. It is therefore now clear not only that their validity is not to be considered 
absolute but also that, if not tailored, probiotic-based interventions could not be 
entirely risk-free.
Future directions will be the adoption of a mechanism-based approach, in which 
probiotic strategies are designed ad hoc, taking into account a series of “precision” 
aspects related to the host and its microbiota, i.e. with careful consideration of the 
subject to be treated and the medical goal to be achieved. It is also expected that 
future human trials will overcome other current caveats in the probiotics field, by 
ensuring an adequate sample size (based on power analysis), clearly defining end-
points, accounting for placebo effects and reporting adverse events, while ensuring 
strain-level resolution [56].
Alongside traditional probiotics, it should be mentioned that novel candidate 
microorganisms with potential health benefits have been discovered thanks to 
recent research on the composition and function of the gut microbiota, deeply 
accelerated by massive sequencing. These microorganisms are referred to as next-
generation probiotics or live biotherapeutics [65], as they fit well within the US 
Food and Drug Administration definition of live biotherapeutic as “a biological 
product that contains live organisms, such as bacteria, is applicable to the pre-
vention, treatment or cure of a disease or condition of human being and is not a 
vaccine”. Unlike currently used probiotics, they are generally strict anaerobes and 
therefore present a number of manufacturing challenges, and they should undergo 
a formal regulatory approval process similar to drugs or any other medical interven-
tion. Among them, we can list SCFA producers, e.g. F. prausnitzii, proposed for the 
treatment of inflammatory bowel disease and other inflammation-based disorders 
[66], or the mucus degrader, Akkermansia muciniphila, identified as a promising 
candidate for the treatment of obesity and related complications [67]. Interestingly, 
a very recent proof-of-concept exploratory study has demonstrated that 3-month 
daily oral administration of live or pasteurized A. muciniphila to overweight/obese 
insulin-resistant volunteers was safe and well tolerated, and associated with numer-
ous metabolic improvements [68].
Alternatively, it has been thought to engineer GRAS organisms or commensals as 
a delivery vehicle for bioactive molecules or to express certain functionality. In this 
approach, the bacterial vehicle is known not to produce any virulence factors, it will 
be tolerated by the host and, if chosen carefully, may not even colonize the host. 
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As an example, some researchers have used Lactococcus lactis strains (normally not 
considered probiotics but GRAS food-derived bacteria) as vehicle to deliver a range 
of anti-inflammatory molecules, e.g. elafin, a serine protease inhibitor, to reduce 
colitis-related inflammation [69], trefoil factor 1, for the treatment of oral mucositis 
[70] and IL-10 to control allergen sensitivity [71]. Other research groups have used 
the common intestinal bacterium Bacteroides ovatus to express IL-2 [72] or TGF-beta 
1 [73], and E. coli Nissle 1917, which was engineered to bind to the surface of cancer 
cells and secrete myrosinase, to convert dietary glucosinolates into isothiocyanates, 
such as sulforaphane, a well-known anti-cancer compound [74].
However, in addition to the limitations discussed above, it should be emphasized 
that for most of these next-generation probiotic candidates, the available evidence 
is currently mostly preclinical, in vitro or on an animal model. Therefore, rigorously 
planned large-scale randomized controlled trials together with in vivo and in vitro 
experimentation are strongly needed for efficacy and long-term safety assessment, 
and data-driven explanation of the mechanisms of action.
In the future it is expected that overcoming all these challenges in the probiotics 
field will improve the state of evidence, regulation of use and, finally yet impor-
tantly, public awareness, for a precision, informed use. The current limitations in 
the field and future strategies to be undertaken to overcome them are summarized 
in Figure 3.
4.  Foods and their prebiotic activities for the modulation of the gut 
microbiota
Food is a primordial need for our survival and well-being. However, diet is not 
only essential to maintain human growth, reproduction and health, but it also mod-
ulates and supports the symbiotic microbial communities that colonize the diges-
tive tract, the gut microbiota. Type, quality and origin of our food shape our gut 
microbes and affect their composition and function, impacting on host–microbe 
interactions. Macronutrients (fat, protein, carbohydrate) and micronutrients (vita-
mins, minerals, polyphenols) directly interact with gut microbes and are involved 
in the production of key metabolites such as SCFAs and vitamins. Moreover, dietary 
fiber impacts on gut microbial ecology, host physiology, and health.
Figure 3. 
From traditional to next-generation probiotics: Current limitations and future directions.
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During or shortly after birth, the human gut is colonized by microbes. The fact 
that babies born spontaneously have higher bacterial counts in the gut at 1 month 
of age than those born by the cesarean section indicates that colonization of the 
gut by microbes starts and is improved during natural birth [75]. The growth and 
maintenance of a healthy gut microbiota is essential for the development of the 
immune system and continues during breastfeeding, a stage that seems essential to 
the individual’s long-term health. Oligosaccharides found in breast milk encourage 
the growth of Lactobacillus and Bifidobacterium, which control the infant intestine, 
and this may improve or facilitate immune system development and help to prevent 
pathological conditions such as eczema and asthma. Functional maturation of the 
human microbiota, including the capacity to produce vitamins, increases during the 
early years of life [76].
A standard Western style diet offers about 50 g daily of potentially fermentable 
substrate, primarily dietary fiber, to the colonic microbiota. Non-starch polysac-
charides are major components of dietary fiber and constitute 20–45% of the dry 
matter supplied to the colon. Simple sugars and oligosaccharides also account for 
another 10%, whereas starch (and starch hydrolysis products) supply less than 8% 
of dry matter. Some sugar alcohols also avoid the absorption of the small intestine 
and are minor dietary substrates for colonic microbiota [77]. Approximately 90% of 
dietary polyphenols (approximately 1 g/day) avoid digestion and absorption in the 
small bowel and can have a major effect on microbial composition and activities.
About 5–15 g of proteins and 5–10 g of lipids, mainly of dietary origin, pass daily 
through the proximal colon. Various other minor dietary constituents, including cat-
echins, lignin, tannins and others, also nourish colonic microbes [78]. The action of 
all these macro and micronutrients is certainly synergistic and complex at the level 
of the intestinal microbiota, however in the following paragraphs we will analyze 
separately the effects of individual macro and micronutrients, trying not to lose the 
overall vision that is fundamental when it comes to microbial ecology.
4.1 Macronutrients and microbiota
Fats. The increase in dietary fats greatly changes the composition of the gut 
microbiota. Mice fed with high-fat diets (HFD, 40–80% of total caloric intake from 
fat) display phylum-level changes, with a decrease in Bacteroidetes and an increase 
in Firmicutes and Proteobacteria.
These changes have also been observed in weight gain-resistant mice, which 
implies a direct effect of dietary lipids on the microbiota. It has recently been 
found that microbes in the small intestine are highly susceptible to fat load and are 
essential for lipid digestion and absorption. These data suggest that the regional 
microbiota composition may have significant functional implications, and highlight 
the need for distinct microbiota and microbiome analysis along the gastrointestinal 
tract [79]. The lipid-mediated effects on the microbiota depend on the form and 
source of lipids. For example, mice fed with an isocaloric diet rich in long-chain 
saturated fats derived primarily from meat products showed greater insulin resis-
tance and inflammation of the adipose tissue compared to mice fed with a high-fish 
oil diet. In addition, transgenic mice that constitutively generate n-3 polyunsatu-
rated fatty acids (PUFAs) have higher phylogenetic diversity of the microbiome, 
which provides protection against the metabolic consequences of a high-saturated, 
high-sugar diet. One mechanism by which gut microbes can mediate the negative 
metabolic effects of high-fat intake could be by translocating LPS, a membrane 
toxin of gram-negative bacteria. An increase in circulating LPS after a high-fat 
meal has also been documented in humans, with amplified effects in obese people. 
Once in circulation, LPS induces a powerful inflammatory response by activating 
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Toll-like 4 receptor signaling, which has been involved in cardiovascular and 
metabolic disease development [80].
Inflammation appears to be the common denominator among the seemingly 
unrelated biological negative effects of fats on the gut microbiome, involving the 
immune system and n-3 PUFAs. It is currently accepted that inflammation plays 
a key role in the progression of several chronic diseases, such as atherosclerosis, 
inflammatory bowel disease, cancer, diabetes, and neurodegenerative syndromes 
[81]. Moreover, as described above, several evidence supports the role of n-3 
PUFAs on the microbiota and on the regulation of inflammation and the immune 
system [82]. In addition, dietary n-3 PUFAs have been shown to reduce clinical 
colitis in IBD patients [83]. In clinical human studies, n-3 PUFA administration 
resulted in decreased Firmicutes/Bacteroidetes ratio, reduced relative abundance 
of Coprococcus and Facecalibacterium, and increased proportions of health-
associated genera, i.e., Bifidobacterium, Lachnospira, Roseburia and Lactobacillus 
[84]. These data were consistent with those obtained in a subsequent study in 
which the authors also found a significant correlation between the plasma levels 
of n-3 PUFAs and the relative abundance of SCFA producers [85]. In addition, 
a diet supplemented with n-3 PUFAs has been able to prevent neuropsychiatric 
disorders and dysbiosis caused by social instability stress during adolescence, and 
these effects have been maintained through adulthood, supporting the concept 
that a healthy diet enriched in fish or n-3 PUFAs can have beneficial long-lasting 
effects and may help to prevent neuropsychiatric disorders [86]. Taken together, all 
these data allow us to hypothesize the existence of a strong link between n-3 PUFA 
intake, gut microbiome shaping and modulation of the immune system, with the 
ultimate objective of hampering the existing loop between bowel inflammation and 
gut dysbiosis.
In the fat dietary component, n-3 PUFAs can rightly be considered prebiotics. 
Therefore, the consumption of an n-3-rich diet is currently thought to be beneficial 
for microbiota health, even if the gut microbiome changes induced in humans by 
n-3 PUFA supplementation deserve further clinical investigations.
What we can conclude for the fat dietary component is that the lipid excess pres-
ent in HFD diet is dangerous for the microbiota and, on the other hand, that a diet 
enriched in n-3 PUFAs protects the microbiota from possible alterations. However, 
n-3 PUFA sources, mainly fish, should not considered completely safe, considering 
the pollution of the sea and the growing presence of microplastics and xenobiotics 
in the trophic chain of marine animals. In particular, scientific data suggest that 
shellfish and other small marine organisms consumed with their intestine pose 
particular concern because they accumulate and retain microplastics. The biological 
effects of microplastics in human gut are poorly understood, but it has been sup-
posed that in high amounts they could cause an alteration of the gut microbiome, 
with cascading effects on host physiology [87].
Proteins. That dietary proteins may affect the gut microbiota was first described 
in 1977. A pioneering study showed lower counts of Bifidobacterium and increased 
counts of Bacteroides and Clostridia in subjects eating a diet enriched in beef meat, 
compared with those eating a vegetarian diet [88]. With advances in metagenomics 
analysis, several studies have been able to investigate in depth the effects of dietary 
protein on the gut microbiota. These studies have evidenced a different effect 
depending on the protein source: animal or vegetarian. While the intake of animal 
meat proteins has been associated with a general worsening of the microbiota 
profile [89], vegetarian protein intake is overall positively associated with microbial 
diversity. For example, intake of pea protein extract has been reported to increase 
the proportions of the gut commensals Bifidobacterium and Lactobacillus. Pea pro-
tein intake was also observed to increase the levels of intestinal SCFAs, considered 
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to be important for several metabolic and immunological aspects, including the 
maintenance of the intestinal barrier. In contrast, counts of bile-tolerant anaerobes, 
such as Bacteroides, Alistipes and Bilophila, increase with animal-based protein 
intake [90]. Notably, different studies comparing high-animal protein diets and 
high-carbohydrate/fiber plant-based diets reported that the first dietary pattern can 
be effective for rapid weight loss but detrimental to microbiota health. In particular, 
the research showed that subjects following a high-protein/low-carbohydrate diet 
were depleted in Roseburia and E. rectale in their gut microbiota with decreased 
butyrate levels in their feces [91]. Other studies confirmed decreased fecal SCFAs 
in Italian subjects eating a protein-rich diet. It has been proposed that high total 
protein intake, especially animal protein, could be associated with a significantly 
increased risk of IBD [89]. In addition, many microbial genera promoted by 
consumption of red meat have been related to increased levels of blood trimethyl-
amine-N-oxide (TMAO), considered a pro-atherogenic marker of cardiovascular 
disease [92]. Finally, it is important to note that animal products-based diets are 
often high both in protein and fat, with potential synergistic negative effects on the 
human microbiota.
Carbohydrates. The effects of dietary carbohydrates on the gut microbiota are 
complex, since they can be classified based on three major components that are 
simple sugars, starches and fiber. Simple sugars such as sucrose, both alone and as 
part of a high-fat/high-sugar Western-style diet, can induce rapid remodeling of 
microbiota and metabolic dysfunction in laboratory animals and also in humans. 
Fibers should be considered as human indigestible carbohydrates. In a healthy 
microbiota, different bacterial genera possess fiber-degrading enzymes and thus 
use these indigestible carbohydrates as a primary source of energy. The term fibbers 
is widely used to classify such indigestible polymers, although this classification 
is problematic given that certain fibers are only partially degraded by intestinal 
microbes (such as cellulose), whereas other are readily fermentable (soluble fibers 
such as inulin). The metabolic effects of fiber are shown in Figure 4. Sonnenburg 
and his colleagues recently proposed the term ‘microbiota-accessible carbohydrates’ 
(MACs), to identify carbohydrates that are metabolically available to gut microbes 
[94]. MACs provide energy and a source of carbon for bacteria but also to the host. 
They can modify the microbiota structure by increasing the populations of fiber-
degrading bacteria. This property of fibers warrants their additional classification 
as prebiotics, which by nature are non-digestible components of the diet that 
support selective growth of certain health-associated microbial populations, such as 
bifidobacteria. Examples of prebiotics include inulin, fructans, fructooligosaccha-
rides, galactoligosaccharides, xyloligosaccharides and arabinoligosaccharides [95]. 
A diet low in prebiotic substances has been shown to reduce total abundance and 
diversity of gut bacteria. In particular, a diet rich in non-digestible carbohydrates 
most consistently increases intestinal bifidobacteria and lactic acid bacteria [96]. 
Other non-digestible carbohydrates, such as resistant starch and whole grain barley, 
also tend to increase the proportions of health-promoting SCFA-producing bacteria 
such as Ruminococcus and Roseburia.
Digestible carbohydrates are enzymatically degraded in the small intestine 
and contain starches and sugars such as glucose, fructose, sucrose and lactose. All 
these compounds release glucose into the bloodstream upon degradation, trigger-
ing an insulin response. Human subjects fed high levels of glucose, fructose and 
sucrose in the form of fruit, had increased relative abundance of bifidobacteria, 
with reduced Bacteroides [97]. Also, lactose supplementation was found to raise 
the fecal amounts of beneficial SCFA-producing bacteria in non-intolerant 
subjects [98].
15
Natural Compounds in the Modulation of the Intestinal Microbiota: Implications in Human…
DOI: http://dx.doi.org/10.5772/intechopen.94043
4.2 Micronutrients and microbiota
Vitamins. Diet is the primary source of vitamins, because our bodies cannot syn-
thesize them to meet our daily needs, but certain vitamins, especially vitamin K and 
the B-group vitamins, are synthesized by some intestinal microbes. As a consequence, 
the abundance and diversity of intestinal microbiota components can modulate the 
metabolism and absorption of vitamins in the upper intestine [99].
The administration of retinoic acid (physiologically active vitamin A metabo-
lite) in patients with norovirus infection significantly increased the abundance 
of Lactobacillus spp. Since Lactobacillus showed antiviral activity in vitro, it has 
been hypothesized that the intake of vitamin A and the consequent increase in 
the amount of Lactobacillus in the gut were partially responsible for norovirus 
inhibition [100]. Retinoic acid administration has also been shown to increase the 
relative abundance of Allobaculum, Aggregatibacter, Bifidobacterium, Dialister and 
Figure 4. 
Fiber intake impacts on host metabolism and immunity by affecting the gut microbiota. Under a fiber-rich 
diet, the gut microbiota metabolizes undigested dietary fiber into SCFAs (acetate, propionate, and butyrate), 
affecting host metabolism and immunity. Microbial metabolites from this process improve host metabolism. In 
particular, the secretion of peptide hormones, such as PYY and GLP-1, is promoted by microbial metabolites: 
PYY decreases appetite and GLP-1 lowers blood glucose level via promotion of insulin secretion. Among SCFAs, 
butyrate and propionate activate intestinal gluconeogenesis and improve systemic glucose profiles. Meanwhile, 
acetate promotes secretion of ghrelin, a hunger hormone, and increases food intake, consequently causing 
hyperphagia and obesity. Nevertheless, acetate has anti-inflammatory function like butyrate. Butyrate enhances 
gut barrier function of intestinal epithelial cells and increases regulatory T (Treg) cells. In addition, the gut 
microbiota suppresses expression of fasting-induced adipose factor (Fiaf), an inhibitor of LPL, promoting fat 
storage in adipocytes. Under fiber-deficient diet, mucus-degrading bacteria expand and impair the integrity 
of the mucus layer. Thereby, endotoxemia-induced metabolic inflammation ensues. SCFAs, short-chain fatty 
acids; PYY, peptide YY; GLP-1, glucagon-like peptide-1; LPL, lipoprotein lipase. From [93].
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Enhydrobacter. Epidemiological studies have shown that norovirus infection rate 
and clinical symptoms decrease significantly with a sufficient supplementation of 
vitamin A [101]. In infants, supplementation of vitamin A showed to improve the 
Bacteroidetes/Bacteroidales population, and increase the relative abundance of 
Bifidobacterium and Akkermansia in feces [102].
Vitamin C is the most important antioxidant agent, and it must be obtained from 
dietary sources (mainly fruits and vegetables). This vitamin regulates the redox state 
and can considerably modulate the gut microbiota. In weaned piglets, vitamin C 
levels correlated positively with Firmicutes and negatively with Bacteroidetes relative 
abundances [103]. Vitamin D is thought to be a multifunctional vitamin involved 
in calcium homeostasis and in a list of systemic physiological functions that include 
the modulation of gut microbiota [104]. A randomized controlled trial showed 
that weekly vitamin D supplementation (50,000 ergocalciferol IU) over 12 months 
increased SCFA fecal levels and the relative abundance of SCFA-producing genera such 
as Ruminococcus, Fecalibacterium and Dialister [105].
Some vitamins of the B group have been shown to promote bacterial coloniza-
tion of the gut, modulate bacterial virulence and participate in pathogen clearance 
[106]. However, they may also have a role in the growth of enteropathogens, such as 
Salmonella Typhimurium [107]. For example, different gut bacteria can synthesize 
vitamin B6, but dysbiosis could reduce the luminal level of vitamin B6 and facilitate 
gut colonization by enteropathogenic strains.
It is evident that there is a high and complex interaction between vitamins 
and the gut microbiota: some vitamins are produced by the microbiota itself and 
others, particularly liposoluble vitamins, are responsible for its modulation. On the 
other hand, some of these vitamins may also contribute to enhanced virulence and 
colonization of potential pathogenic microbes. These studies together suggest that 
vitamin supplementation could modulate the gut microbiota, but its effects depend 
on the level of vitamin in the host and the microbiota status. Further clinical trials 
should be carried out to understand the effects of multivitamin supplementation, in 
order to evaluate possible effects linked to over-supplementation.
Polyphenols. Dietary polyphenols are studied for their antioxidant properties. 
Popular foods with a rich content of polyphenols include fruits, nuts, vegetables, 
tea, cocoa, and wine. For example, the relative abundance of Bacteroides was 
reported to increase in subjects consuming pomegranate [108]. The consumption of 
cocoa-derived polyphenols has been associated with significant changes in the gut 
microbiome [109]. Fruit seed, wine and tea polyphenols were capable to posi-
tively modulate the human fecal microbiota by affecting the levels of pathogenic 
Clostridium species (C. perfringens and C. histolyticum) [110].
Conceptually, it is difficult to isolate the activity of polyphenols from the overall 
activity of the foods that contain them. Nevertheless, overall we can conclude that 
a diet rich in foods with high polyphenol content, can have positive effects on the 
human intestinal microbiota.
Food additives and xenobiotics. Another poorly understood area with potential 
implications for the human gut microbiota health is the impact of food additives 
and xenobiotics on the microbial ecology and intestinal homeostasis. Although 
Western diets typically attribute microbial and health consequences to macronutri-
ent composition, several studies suggest that food additives may be driving the 
detrimental effects of these diets on the microbiota. For example, in the absence of 
other dietary manipulations in mice, two dietary emulsifiers, polysorbate-80 and 
carboxymethyl cellulose, induced obesity, intestinal inflammation, metabolic dys-
function and dysbiosis. The microbiota was both necessary and sufficient to explain 
all these effects as germ-free mice were protected from these detrimental effects, 
and the transfer of microbiota from emulsifier-treated mice was sufficient to 
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recapitulate the metabolic disruptions [111]. These results are particularly striking 
considering the wide range of foods containing emulsifiers (for example gluten-free 
and reduced-fat products, ice cream, and pickles), and that the doses used in this 
study reflect the human intake. Non-nutrient sweeteners (NNSs) have been linked 
to gut-associated metabolic alterations, in addition to emulsifiers. In experiments 
conducted in rodents and humans, NNS consumption induced glucose intolerance 
in a microbiota-dependent manner [112]. Nevertheless, literature data on the effects 
of NNSs on intestinal microbiota and microbiome sometimes are divergent, and 
this is also dependent on the fact that NNSs are a broad class of substances with 
high structural and functional variability. Additional human intervention stud-
ies examining the impact of individual NNSs on microbiota and microbiome are 
certainly needed.
Artificial sweeteners such as saccharin, sucralose and aspartame have been con-
sidered as options that might be used to replace natural sugar to prevent and control 
glucose dysmetabolism. However, recent evidence suggests that consumption of 
all types of artificial sweeteners may induce glucose intolerance. It is important to 
note that artificial sweeteners are thought to mediate this effect also by altering the 
gut microbiota. For example, it was noted that saccharin-fed mice had intestinal 
dysbiosis with increased relative abundance of Bacteroides and reduced Lactobacillus 
reuteri [112].
Even on the large category of xenobiotics it is very difficult if not impossible to 
generalize. Just as an example, analysis of the microbiome of children with Crohn’s 
disease developed at a very young age showed that the most altered metabolic patterns 
in the gut microbiome were those related to xenobiotic metabolism [113].
4.3 Dietary patterns
Several popular diets have been studied for their ability to modulate the intes-
tinal microbiota, including Western, ketogenic, omnivore, vegetarian, vegan and 
Mediterranean diets. The Western diet (high in animal protein and fat, low in fiber) 
has led in several studies to a marked decrease in microbial diversity and in some 
beneficial genera, such as Bifidobacterium and Eubacterium [114].
Ketogenic diets are characterized by a very low consumption of carbohydrates (5 
to 10 percent of total caloric intake), sufficient to increase the production of ketone 
bodies. They were originally developed as a treatment for refractory childhood 
epilepsy, and the gut microbiota responses to a ketogenic diet seem to play a role in 
the effectiveness of this intervention in epileptic infants [41, 42]. In recent years, 
these diets are commonly adopted in order to obtain rapid weight loss and in some 
studies, they have been shown to improve longevity and reduce the onset of disease 
in experimental animals. Conversely, some human studies in which ketogenic diets 
were examined, suggest negative impacts on microbial ecology and gut health. These 
studies, however, were carried out in small cohorts with specific metabolic condi-
tions, limiting the generalization to larger populations [115]
Vegan/vegetarian diets are both plant-rich diets associated with positive health 
outcomes and reduced risk of some diseases [116]. The beneficial effects of these 
diets on human health could also be linked to intestinal microbiota modulation. 
Plant-based foods are the primary source of dietary MACs, and it has been found 
that individuals who consume vegetarian or predominantly plant-based diets have a 
microbiota metabolically optimized for MAC fermentation. However, some inter-
vention and cross-sectional studies have found only modest differences in micro-
biota composition between omnivores and vegetarians, and suggest that the effects 
of dietary patterns on the microbiota are greatest at the level of genus and species, 
but relatively minimal on broader compositional features such as diversity [117].  
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Despite the absence of a wide microbiota compositional shift, the species-level 
changes appear to be sufficient to alter metabolic outputs as SCFA production, 
which in vegetarians is typically increased. It is still unclear to what extent these 
microbiota-dependent metabolic outputs can mediate the beneficial effects of 
vegetarian diets.
Plant-based foods, in addition to supplying MACs, provide a diverse source of 
vitamins, polyphenols and other biologically active phytochemicals. Many phyto-
chemicals may often reach the lower intestinal tract and have direct antimicrobial 
and anti-inflammatory effects in the intestine. Furthermore, microbial enzymes can 
modify phytochemicals into metabolites with increased bioactivity [118, 119]. So, 
microbiome-mediated changes in phytochemical bioavailability can be an additional 
mechanism underlying the beneficial effects of plant-based diets.
Several studies classify the Mediterranean diet as the most healthy and balanced 
human diet. It is characterized by a beneficial fatty acid profile, rich in both monoun-
saturated and polyunsaturated fatty acids, high polyphenols and other antioxidants 
and high fiber intake. Fruits, vegetables, cereals, legumes and nuts are at the basis of 
this diet, as well as consumption of fish and red wine [120]. The potential benefits of 
Mediterranean diet on the gut microbiota are linked to the increased levels of fecal 
SCFAs together with an increase of Prevotella, Lactobacillus and Bifidobacterium, and a 
decrease in Clostridium [92].
Even if there are different types of Mediterranean diet, as well as several 
ketogenic diets (e.g. normo- or iper-proteic) and even vegetarian diets (with or 
without eggs, with or without fish), what can be concluded in general about the 
effects of dietary patterns on the intestinal microbiota is that all those patterns 
which, for various reasons, tend to restrict the amount of vegetables, seem to be 
inadvisable. Thus the Western diet, which is poor in fruit and vegetables, and the 
ketogenic diets, which necessarily eliminate fruit for its carbohydrate content, 
appear to be diets with a probable negative impact on the intestinal microbial ecol-
ogy. Despite this, comparative controlled clinical trials are needed to fully evaluate 
the possible short-term and long-term effects of these dietary patterns on the gut 
microbiome.
5.  Use of fungus and officinal plants for the modulation of the intestinal 
microbiota and immune system
Microbiota and its multiple connections, already described in the previous 
paragraphs, remind us that every human being is an unrepeatable and unique 
Psycho-Neuro-Endocrine-Immuno-Somatic-Environmental unit that is constantly 
dynamic and interactive in its parts [121]. From this perspective, the gastrointestinal 
system should be evaluated and treated as a neuro-immuno-endocrine-visceral-
microbial interface of the human body. The modulation of the gut microbiota and, 
consequently, of the immune system is a key function of this complex network. Any 
disorder of the gastrointestinal tract, be it functional or with organic inflammatory 
basis, involves cells belonging to multiple tissues, including the sphere of the micro-
biota, and is therefore continuously reflected at the systemic level.
Consequently, even medicinal plants can, indeed should, act at multiple levels 
of the organism through direct and indirect actions that certainly, with various 
types of mechanisms, involve the Intestinal Immune System (IIS) and the intestinal 
microbiota. The action of fungi and medicinal plants is exerted on the gastrointes-
tinal system through the immunomodulating, antioxidant and protective properties 
of the microbiota. Furthermore, the protection of the biofilm and the intestinal 
barrier, in the structuring of which the microbiota directly and actively participates, 
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also fall within these therapeutic actions. These effects on the intestinal barrier and 
on the gastrointestinal system can obviously also have systemic consequences.
Several medicinal plants and fungi are described in the scientific literature as 
being able to act positively on various acute and chronic inflammatory disorders of 
the gastrointestinal system, most of these are also part of the medical tradition of 
one or more regions of the world.
Medicinal mushrooms that have been used in most preclinical and clinical 
studies are Hericium erinaceus, Inonotus obliquus (called Chaga), Ganoderma lucidum 
(called Reischi), and Auricularia auricula. Instead, the most used medicinal plants 
for the gut are Boswellia serrata, Pistacia lenticus, and Aloe in its various species. 
With a mainly European traditional use, we find Olea europea (olive tree), Angelica 
arcangelica, Achillea millefolia, Cichorium intybus and finally Cetraria islandica, 
which belongs to the lichen species.
In this brief discussion, we will limit ourselves to analyzing the scientific litera-
ture supporting possible therapeutic use of some of these fungi and these plants, in 
the modulation of intestinal inflammation and dysbiosis, the two components that 
are always associated in almost all pathologies of the gastrointestinal tract.
5.1 Microbiota-modulating fungi
Hericium erinaceus represents the most used fungus for all the disorders of the 
gastrointestinal system. Also known as Lion’s Mane Mushroom, is an edible fungus, 
which has a long history of usage in traditional Chinese medicine for the protec-
tion of mucous membranes, gastric ulcers, acute and chronic gastritis and nervous 
degeneration [122–124].
The drugs used are the fruiting body and/or the mycelium in aqueous or hydroal-
coholic or alcoholic extracts titrated and standardized in one or more of the following 
components: polysaccharides and beta-glucans (with anti-inflammatory and antibac-
terial action), alpha-glucans, diterpenes and triterpenes and polyphenols [125, 126].
The most studied activities of this fungus relate to its immunomodulatory 
effects on the gut, its anti-inflammatory systemic activity, but also its prebiotic 
activities on the intestinal microbiota [127].
A single protein, called HEP3, isolated from H. erinaceus and administered to 
rats treated with trinitrobenzenesulfonic acid (TNBS) to induce experimental 
colitis similar to IBD, was capable of restoring the microbiota diversity in treated 
rats. In particular, treatment with H. erinaceus single protein increased the amounts 
of Actinobacteria and Tenericutes, reduced those of Bacteroidetes and Firmicutes, 
and was able to restore a healthy-like ecological structure [128, 129]. The effec-
tiveness of HEP3 was also confirmed in other animal models of colitis [130]. We 
would like to underline the general concept that it is always advisable to use titrated 
extracts with greater complexity than single proteins, as these extracts can keep the 
phytocomplexes and mycocomplex intact, and in vivo could have synergistic actions 
on multiple targets. Also, raw extracts of H. erinaceus were tested in an IBD animal 
model as whole polysaccharide, alcoholic extract or whole extract. Results indicate 
that all these formulations were capable of positively modulating the microbiota, 
but while the polysaccharide extract seems to play a major prebiotic role, the alco-
holic extract and whole extract showed major bactericidin-like effects [128, 129].
Similar results were obtained in a model of dextran sulfate sodium (DSS)-
induced colitis in mice. DSS treatment resulted in increased relative abundances 
of Verrucomicrobia and Actinobacteria and decreased amounts of Bacteroidetes 
in fecal samples, compared to the control group. Treatment of colitic mice with 
dry power of fermented H. erinaceus mycelium reversed most changes, including 
the increased levels of A. muciniphila. Collectively, these results showed that H. 
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erinaceus effectively modulate the gut microbiota of colitic animals, restoring a 
microbiota composition similar to that of healthy mice [131].
Inonotus obliquus commonly known as Chaga is a parasitic fungus mainly of 
Birch (Betulaceae) trees with numerous biological properties [132, 133]. Commonly 
used as a folk remedy in Russia and other northern European countries for various 
disorders affecting the digestive system, it is now widely studied for its numer-
ous potential applications in the medical field. The most used formulations are 
powder, aqueous extract and hydroalcoholic extract. These can be titrated in 
polysaccharides, beta-glucans, alpha-glucans and polyphenols. Even the fungus 
I. obliquus has been successfully used to counteract the effects of DSS-induced 
colitis in mice [134]. Its major effects seem to be the modulation of IIS [Won et al., 
2011]. Nevertheless, its polysaccharides showed a positive regulatory effect on the 
microbiota in animal models of colitis. In a chronic pancreatitis mice model, the 
compromised microbiota profile was partially restored by I. obliquus polysaccha-
rides administration, which was able to increase microbiota diversity and richness 
and also to improve mouse clinical conditions [93].
Ganoderma lucidum (in Japanese called Reishi) is considered, in the Far East, 
the mushroom of immortality due to the countless biological activities it would 
be able to promote. It is a mushroom with a woody texture and a bitter taste, 
which grows preferably on oaks and chestnut trees. The main traditional use in 
China and Japan is aimed to counteract allergic and inflammatory status [136] but 
its traditional use also covers hypertension, liver and cardiovascular problems. 
Recent studies have identified more than 400 bioactive molecules present in 
this mushroom. Some of these were identified for the first time in this specie, 
and consequently named as ganoderiol, ganolucidinic acids, and ganoderman-
triol [137].
The most studied activities of this mushroom are the immunostimulatory effect 
exerted on the gut but also at systemic level. However, there is also evidence of 
prebiotic activity on the microbiota, although this could be secondary to a direct 
effect on immune system components. Its powerful immunomodulatory effects led 
to extend its field of use also to the therapy of tumors, a topic which, however, goes 
beyond the themes of this chapter [138]. In DSS-induced colitis in rats, G. lucidum 
β-glucans increased SCFA-producing bacteria such as Ruminococcus, and reduced 
pathobionts such as Escherichia and Shigella in both the small intestine and cecum 
[139]. In mice fed a HFD, which showed increased body weight, gut and systemic 
inflammation and insulin resistance, treatment with G. lucidum mycelium reversed 
the HFD-induced gut dysbiosis, decreasing the Firmicutes-to-Bacteroidetes ratio 
and the Proteobacteria levels. Moreover, Reishi treatment reduced metabolic endo-
toxemia by restoring the intestinal barrier integrity. These anti-obesity effects were 
transmissible via fecal transfer from G. lucidum-treated mice to untreated HFD-
fed mice, demonstrating that the leading mechanism of action of G. lucidum was 
linked to the modulation of the microbiota. High molecular weight polysaccharides 
(>300 kDa) present in G. lucidum were capable of producing similar microbiota 
modulation and anti-obesity effects [140]. Similar results were obtained in a rat 
model of type 2 diabetes, in which G. lucidum treatment reduced the relative abun-
dance of harmful bacteria, such as Aerococcus, Ruminococcus, Corynebacterium and 
Proteus, and increased the levels of Blautia, Dehalobacterium, Parabacteroides and 
Bacteroides. Microbiome analysis indicated that Reishi treatment could also restore 
the microbial metabolism of amino acids, carbohydrates, inflammatory substances 
and nucleic acids, altered by the obesity status [141, 142]. Taken together, these 
results indicate that G. lucidum and particularly its high molecular weight polysac-
charides may be effectively used as prebiotic agents to prevent gut dysbiosis and 
obesity-related metabolic disorders, at least in obese rodents.
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In a mouse model of pancreatitis, induced by diethyldithiocarbamate (DDC), 
polysaccharides from G. lucidum were capable of positively modulating the gut 
microbiota, by decreasing the relative abundance of Bacteroidetes and increasing 
that of Firmicutes. At the genus level, supplementation of Reishi polysaccharides 
increased the relative abundance of beneficial bacteria, such as Lactobacillales, 
Roseburia and Lachnospiraceae. These results confirmed that also the therapeutic 
mechanism on chronic pancreatitis might be dependent on the restoration of a 
eubiotic intestinal microbiota layout [16, 17].
Finally, it should be emphasized that even if all these mushroom preparations 
can be easily found for free sale, and even if they do not seem to have side effects, it 
is a good practice to never use them in self-prescriptions as their direct interactions 
with drugs, or their effects on detoxifying enzymes such as CYP, have not yet been 
studied or poorly known. For example, Chaga extract inhibited platelet aggregation 
in mice. It may also have synergistic effects when used with anticoagulant/anti-
platelet drugs, but the clinical relevance in humans is not known [143]. Chaga may 
also interact with hypoglycemic agents drugs, since it has demonstrated to possess 
hypoglycemic activity in animals [144, 145]. A single case-report described oxalate 
nephropathy as a side effect associated with the ingestion of Chaga mushroom 
powder (4–5 teaspoons daily for 6 months), in a 72-year-old Japanese woman with 
liver cancer [146].
Chaga effects on detoxifying enzymes such as CYP have not yet been studied. 
Reishi may increase the risk of bleeding, interfering with anticoagulants/antiplate-
lets drugs [147]. Reishi can also enhance immune response and this effect should 
be taken into account in patients on immunosuppressive therapy. Finally, at least in 
vitro, Reishi polysaccharides inhibited many different CYP enzymes [148].
5.2 Microbiota-modulating plants
Cichorium intybus is a perennial herbaceous plant whose rhizome and roots are 
traditionally used in Europe to treat gastrointestinal disorders [149]. It has been 
tested in farmed broiler chickens in order to improve productive performance, and 
showed to induce changes in ileal microbiota consisting of lower counts of E. coli 
and higher counts of Lactobacillus. These effects were associated with improved 
growth performance. Dietary chicory powder supported ileal microbiota ecol-
ogy probably by acting as a prebiotic, since it has a high content in soluble fibers, 
particularly inulin [150]. In mice fed with different chicory genotypes, all prepara-
tions were capable of modifying the fecal microbiota by modulating the Firmicutes/
Bacteroidetes ratio and some bacterial genera, such as Alloprevotella, Blautia, 
Alistipes, and Oscillibacter, with a variable effect depending on the chicory geno-
type. In addition to microbiota changes, some modifications in the release of satiety 
hormones, and as a consequence appetite, were also observed in mice treated with 
C. intybus [151].
Boswellia serrata is an arboreal plant that forms an aromatic resin also known 
as frankincense. The B. serrata resin has been used as supplementation in rabbit 
diets at different dosages to observe variations in the cecal microbiota. Substantial 
changes in microbial cecal populations were found in rabbits treated with B. serrata, 
with a significant decrease of total bacterial counts and in particular a decrease of 
Salmonella enteritidis and E. coli if compared to the control untreated rabbit group. 
These results could be ascribed to the high polyphenol content in B. serrata and to 
the presence of Boswellic acid that holds a powerful anti-microbial effect [152, 153].
Pistacia lentiscus is a shrub or small evergreen tree that produces a resin called 
Chios mastic gum, used as a natural food supplement. The effect of P. lentiscus was 
investigated in mice with obesity, nonalcoholic steatohepatitis (NASH), and liver 
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fibrosis induced by HFD. Treatment with P. lentiscus promoted a partial but signifi-
cant recovery of microbiota diversity associated with a decrease in Bacteroidia and 
an increase in Proteobacteria relative abundance [154].
Olea europaea is an evergreen fruit tree found traditionally in the Mediterranean 
area. O. europaea extra virgin oil (EVO) obtained from its fruits, olives, is able 
to induce higher gut microbiota biodiversity and promote the growth of ben-
eficial commensal bacteria, as showed by studies on humans and animals [155]. 
Nevertheless, the traditional use of O. europaea as officinal plants is limited to 
its leaf preparations. O. europaea leaf extract administered to obese mice was 
capable of improving the gut microbiota by partially restoring the amounts of 
Actinobacteria, Bacteroidetes and Verrumicrobia. Also, the relative abundance of 
Akkermansia spp. was restored, suggesting a possible effect on intestinal barrier 
function in treated mice [156].
As for Angelica arcangelica, Achillea millefolia, and Cetraria islandica, officinal 
plants that are traditionally used to treat intestinal dysbiosis and inflammation, 
there are no scientific studies so far published to support their positive action on 
the intestinal microbiota and microbiome. This does not mean that these medicinal 
plants are not effective in modulating the gut microbial ecology, but only that the 
documented scientific evidence of their supposed therapeutic activities are still 
very poor.
6. Aromatic plants end essential oils (EOs) as bowel “Eubiotics”
6.1  Intestinal microbiota modulation exerted by essential oils and aromatic 
plants
Aromatic plants are a wide group of herbs with characteristics aroma 
due to the presence of high amounts of volatile compounds known as EOs. 
Consequently, aromatic plants have always constituted a characteristic aspect of 
the gastronomic traditions. In recent years, the use of these aromatic plants has 
been replaced, especially in countries with high per capita income, with artificial 
flavors that allow the elaboration of more sophisticated aromas that in many 
cases are kept secret by the food industry, to avoid plagiarism. This replacement 
is certainly part of the transition from the traditional cuisines to the so-called 
western diet, the process called westernization of the diet that has taken place 
in many countries, parallel to the increase in the incidence of many intestinal 
diseases related to alterations of the gut microbioma, such as Inflammatory Bowel 
Diseases (IBD) [157]. EOs have multitarget effects on the intestine due to their 
antioxidant, anti-inflammatory but also antimicrobial properties directed on the 
bacterial, yeasts, fungi and viruses components of the human microbioma [158]. 
The antibacterial activity of EOs depends on the concentration that they reach 
into the gut, but also on the species of bacteria that they encounter. In fact, some 
OEs have more marked effects (i.e. lower Minimum Inhibitory Concentrations 
or MICs) for bacterial species considered pathogenic, while showing less activity 
(i.e. higher MICs) towards components of the microbiota such as bifidobacteria 
and lactobacilli [159]. This multitarget positive effects of EOs on the intestinal 
microbiota, different from those obtained with the use of probiotics and prebiot-
ics, has not found a definition in the literature yet. Hence, we propose here for the 
first time the term “eubiotic” activity since EOs restore the intestinal microbiota 
back to a physiological state of eubiosis, when a dysbiosis has been established 
into the gut.
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6.2 Eubiotic proprieties of EOs on gut microbiota of animals and humans
There is no doubt that EOs are able to modulate the intestinal microbioma for 
their antimicrobial activities, which is one of the reasons why nature has selected 
these complex mixtures of active molecules with evolution. EOs may have “eubiotic” 
effects thanks to their capability to control and modulate bacterial growth, acting 
both as bacteriostatic or bactericidal agents [160]. In fact, due to their lipophilic 
properties, EOs can penetrate membranes, and damage bacterial cells structure 
making their membranes more unstable and permeable. Membrane disruption may 
also lead to bacterial death caused by the significant leak of ions and other essential 
cytosolic components. These EO effects are generally more pronounced on Gram 
positive bacteria respect to Gram negative ones [161]. However, it has been demon-
strated that EOs can also affect bacterial cell wall in Gram-negative bacterial strains 
[162]. Despite this, there are very few clinical studies of their eubiotic activity on 
humans, while the scientific data obtained on animals bred for human consumption 
or on experimental animal models are numerous and really convincing.
In broiler chickens, EOs have been widely adopted to improve intestinal microbi-
ota and, as a consequence, to boost the growth performances of farmed animals. For 
example, the effects of liquidambar essential oils (LEO) isolated from Turkish sweet 
gum leaves (Liquidambar orientalis Mill.) were a decreased Escherichia coli counts in 
jejunum, associated with an increased weight of chickens after 42 days of treatment 
[163]. Feeding broilers with a trade mark EO mixture containing thymol (Thymus 
vulgaris), eugenol (Cinnamomum spp.), and piperine (Piper spp.) resulted in an 
increase in Lactobacillus and a decrease in E. coli counts in ileal microbiota, associ-
ated with an increased food conversion ratio [164]. In another study, the adminis-
tration of a commercial EO mixture, containing cinnamaldehyde, isophorone and 
eugenol significantly increased the relative abundance of phyla Bacteroidetes and 
decreased the abundance of phyla Firmicutes in cecal microbiota of chickens, with 
an increase in the relative abundance of genus of Alistipes, Rikenellaceae, Roseburia, 
and Anaeroplasma. This microbioma changes was confirmed by more than hundred 
different metabolites detected in cecum of EO treated animals, probably linked to 
their improved growth performances [141, 142].
Broiler chicken is not the only farmed animal treated with EOs for the purpose 
of modifying microbiota and reduce the susceptibility to infection by pathogenic 
bacteria. In farmed rainbow trout, the treatment with a mixed EO (containing 
eucalyptus, oregano, thyme and sweet orange EOs) caused significant microbiota 
changes in alpha and beta diversity, increasing also their growth performance and 
the final product quality. [165]. In farmed pigs, oral administration of a EO mixture 
(containing cinnamon and oregano EOs) caused a significant decrease of infections 
caused by two porcine diarrhetic enterotoxigenic E. coli strains [166].
Two different essential oils were tested on farmed ducks, again in order to 
improve their growth performance and also to replace the use of antibiotics in 
animal farming. One consisted of oregano oil, the second of thyme and cinnamon 
oil. Both of these EO preparations were able to decrease the cecal populations of 
coliforms and lactose-negative enterobacteria, demonstrating also in these animals 
an eubiotic effect of these OE on the gut microbiota [167].
Even on farmed crustaceans, a blend of organic acids and essential oils was 
tested for the improvement gut microbiota and disease resistance of Pacific white 
shrimps. Results demonstrated that this mixture was capable to enhance microbiota 
diversity and richness, increasing the abundance of Firmicutes and reducing the 
abundance of Proteobacteria. Also, a significant increase in the abundance of 
Lactobacillus was observed in shrimp gut [125, 126].
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All these studies as a whole demonstrate without doubt the eubiotic potential 
of orally administered EOs. Furthermore, they clearly demonstrate that dos-
ages effective for modulating the microbiota are free of toxic effects on animals. 
Nevertheless, it remains rather difficult to understand which components of EOs 
are most active for modulating the microbiota, because of their natural complexity 
and their use in mixtures. For these reasons, several studies have explored the eubi-
otic properties of EO single molecules. The most studied was certainly geraniol, for 
its interesting antimicrobial potential. Geraniol antibacterial activity seems to be 
linked to his property to destabilize bacterial cell wall and damage transmembrane 
efflux pumps [168]. Despite being absorbed very quickly and in an active man-
ner by the small intestine mucosa, geraniol is reported to positively modulate the 
colitis-associated dysbiosis when administered by oral route by using a controlled 
delivery system based on microencapsulation [169]. In mice but also in humans, 
geraniol has demonstrated to act as an excellent modulator of intestinal microbiota, 
capable to boost populations of butyrate-producer bacteria such as Collinsella and 
Faecalibacterium, normally reduced in the dysbiotic human intestinal flora of IBS 
patients [157]. It is interesting to note how geraniol antibacterial activities is quite 
selective for pathogenic bacteria and do not involve commensal species [159]. For 
these reasons, geraniol can be considered as an efficient eubiotic for the human gut 
microbiota.
Another interesting EO molecule with antibacterial activities is eugenol 
(2-Methoxy-4-(prop-2-en-1-yl) phenol), the major compound present in clove 
oil, but also found in many other EOs. Eugenol has demonstrated antimicrobial 
activities based on a non-specific permeabilization of the bacterial membrane with 
depletion of adenosin triphosphate (ATP), an energy moiety necessary for bacterial 
metabolism and survival [170]. This effect has been observed against gut pathobi-
onts such as E. coli, Listeria monocytogenes and Lactobacillus sakei at the relatively 
low concentration of 10 mM [171]. In mice, orally administrated eugenol improved 
the secretion of the intestinal mucus, creating a thicker intestinal layer associated 
with positive changes of the mucosal-microbiota ecology. In particular, eugenol 
inhibited the intestinal adherence of Citrobacter rodentium, a mice pathogen that 
shares several biochemical features with Clostridium difficile in humans [172]. It 
would be really interesting to use eugenol in a clinical study aimed at the eradica-
tion of C. difficile: the results could be surprising.
Cinnamaldehyde (2E-3-Phenylprop-2-enal) is a phenylpropanoid naturally 
present in the plant of the genus Cinnamon. Cinnamaldehyde is one of the most 
studied EO molecule and it has been already approved as antimicrobial food preser-
vative [173]. Antibacterial effects of cinnamaldehyde have been demonstrated by 
using many different bacterial models, but only few studies evaluated its impact on 
the whole intestinal microbiota. In vitro, cinnamaldehyde was capable to inhibit the 
growth of potentially pathogenic bacteria such as S. aureus, E. cloacae, A. bauman-
nii and L. monocytogenes [174] and it was able to kill a pathogenic strand of E. coli 
at very low concentrations (0,05% v/v) [175]. One of the proposed antibacterial 
mechanisms of cinnamaldehyde inhibition of E. coli growth was the inactivation of 
its acetyl-CoA carboxylase enzyme [176]. Other studies showed that cinnamalde-
hyde antimicrobial activity has a broad spectrum of action, being effective against 
many different intestinal pathobionts such as Enterococcus faecalis, Enterococcus fae-
cium, E. aerogenes Salmonella enterica and Clostridium perfringens [177]. In vivo, only 
few studies have been conducted on cinnamaldehyde, perhaps because of its strong 
aggressiveness towards the mucosal epithelia. Nevertheless, in animal experimental 
colitis, the oral administration of cinnamon EO (approx. 70% in Cinnamaldehyde) 
at 10 mg/Kg or 15 mg/Kg lead to an improvement of the ecological biodiversity 
of the intestinal microbiota. Short-chain fatty acids (SCFA)-producing bacteria 
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family, such as Bacteroidaceae, were increased while intestinal Helicobacter and 
Bacteroides were reduced [178].
Other molecules, such as thymol do not seem to show eubiotic effects in the gut, 
being non-selective and affecting all the intestinal bacteria and therefore behaving 
like a broad-spectrum antibiotics, depleting the microbiota even when administered 
at low dosages with a negative impact also on commensal bacteria [159].
Carvacrol, a major component of oregano EO, showed to inhibit bacterial adhe-
sion, invasion and biofilm development in cultured intestinal cells [144, 145]. In 
farmed broiler, treatment with carvacrol-rich EO was tested to control the patho-
genic bacteria spreading inside the farms. Results of these studies demonstrated 
that carvacrol reduced the microbial counts of E. coli and different Salmonella 
species in the small intestine of farmed chicken [144, 145]. Moreover, carvacrol 
administration to broiler chickens, was capable to eliminate the intestinal presence 
of Campylobacter spp. after 21 days of oral daily administration at 120–300 mg/Kg. 
This effect was associated to the enhanced growth of Lactobacillus, that were found 
to be increased in chicken microbiota, after carvacrol administration. For its eubi-
otic activity, this molecule is today the most used in organic chicken farming [179].
Limonene (1-Methyl-4-(prop-1-en-2-yl) cyclohex-1-ene) is a cyclic mono-
terpene present in high amount in EO of citrus fruit peels that has widely 
demonstrated antimicrobial and eubiotic effects in vivo. In mice, daily oral 
administration of 160 mg (8.000 mg/Kg) of limonene-rich orange EO modulated 
the gut microbiota by enhancing the relative abundance of Lactobacillus genus 
and of Bifidobacterium population [180]. Despite the low toxicity of limonene, it 
should be noted that these eubiotic effects were obtained only with high dosages 
of this EO.
Eucalyptol (1,3,3-Trimethyl-2-oxabicyclo[2.2.2]octane) is a cyclic ether and a 
monoterpenoid. It is the major compound in Eucalyptus EO, but it can be also found 
in many other officinal plants. Eucalyptus EO has extraordinary antimicrobial 
activities and has shown to be effective against a plethora of bacteria species and 
among them S. aureus, E. coli, Bacillus subtilis, Klebsiella pneumonia, Salmonella 
enteritidis and P. aeruginosa [181]. Nevertheless, Eucalyptus EO also contains high 
amounts of other antimicrobial components besides eucalyptol, therefore not all of 
Eucalyptus EO antibacterial activity can be ascribed to the presence of eucalyptol. 
However, literature data regarding eucalyptol eubiotic activity are very limited, and 
new studies focused on this interesting compound are needed.
Menthol (5-Methyl-2-(propan-2-yl)cyclohexan-1-ol) is a chiral alcohol and the 
main molecule present in cornmint and peppermint EOs. It has been well known for 
its use in foods as a cooling and minty-smell aroma. Many in vitro studies focused 
on its antibacterial activities [182]. Nevertheless, studies on the use in vivo of 
menthol alone, to modulate the gut microbiota, are lacking.
6.3 EOs in the modulation of gut mycobiome
Fungi were reported to represent about 0,1% of all the microorganisms pres-
ent in the gastrointestinal tracts. Maybe also for this reason, despite the presence 
of fungi in the intestine has been known for many years, in depth studies of the 
human mycobiome were only recently performed [183]. Together with bacteria, 
fungi contribute to the modulation of the intestinal immune system [184]. Many of 
them have a clear pathogenic potential even if, physiologically, they are commensals 
in our bodies. Only in some specific conditions their overgrowth can lead to well-
known mycosis. The best known fungal pathogen of humans is certainly Candida 
albicans, which is a normal component of the gut mycobiota but may causes can-
didiasis in case of its intestinal and vaginal overgrowth [185]. An altered intestinal 
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mycobiota has also been observed in other human pathological conditions, such 
as IBS [186], inflammatory bowel disease (IBD) [187] and also autism-spectrum 
disorders and Rett syndrome [188].
EOs antimycotic activities are characterized by a broad spectrum of actions 
[189]. C. albicans has been one of the main target for studies focusing the antifungal 
effect of EOs and their single molecules. The antifungal activities of EO obtained 
from Thymus vulgaris, Citrus limonum, Pelargonium graveolens, Cinnamomum cassia, 
Ocimum basilicum, and Eugenia caryophyllus have been evaluated against clinical iso-
lates of C. albicans and C. glabrata. All of these EOs exhibited both fungistatic and 
fungicidal activity towards these two Candida species, but cinnamon oil demon-
strated the highest activity [190]. Since the most represented active compounds of 
Cinnamomum EO is cinnamaldehyde, many studies have been addressed to analyze 
in depth its activity against C. albicans [191].
Limonene has shown to possess strong antifungal properties [192] and in 
particular an excellent anti-Candida activity. A recent study analyzed the efficacy 
of this compound against the growth of C. albicans isolates, whose growth was 
completely inhibited at doses ranging between 5 mM and 20 mM [193].
Mentha EOs have demonstrated good antimycotic activities against different 
fungi genus, including Candida [194]. Menthol and (+)-carvone are the major 
components of peppermint EO and both exhibited strong antifungal activity in 
vitro [195] and mycobiome modulation activities in vivo [196].
Thymus vulgaris EO has also shown to be effective against fungi pathobionts 
capable to infect humans. A study on Dermatophyte, fungi that can cause superfi-
cial infections of the skin, and on Aspergillus, fungus genera that can cause respira-
tory infections, reported MIC values for Thymus vulgaris EO ranging from 0.16 to 
0.32 μl/ml. Higher MIC values, between 0.32 and 0.64 μl/ml, were reported for 
Candida spp. The antifungal activity of this EO has been attributed to its two major 
components: thymol and carvacrol, that accounted respectively 26% and 21% of 
Thymus vulgaris EO [196]. Both these phenolic compounds seem to act by disrupt-
ing the fungal cell membranes [161].
Clove EO has been traditionally used in dentistry for its anesthetic and antimicro-
bial activities [197]. Its anti-fungal action has been attributed to eugenol, the major 
clove oil molecule. A recent study indicated that Clove EO, at concentrations that 
ranged between 0,03% and 0.25% (v/v), inhibited the biofilm formation in many 
Candida species, grown on different substrates [198]. For what the mechanism of 
action concerns, eugenol was able to cause permanent injury to the cell membranes 
of C. albicans and morphological alterations to its cell wall [161, 199]. Although 
these studies suggest that the eubiotic effect of EOs and their individual chemical 
compounds may also be extended to the mycobiome, there is currently no conclusive 
evidence showing that the improvement in microbial ecology linked to the use of 
these compounds can also involve the fungal component of the human microbiota.
EOs have also been shown to have strong antiviral activities, which could affect 
the gut virome, which is an integral part of the human microbiota [200]. To date, no 
study has been performed to understand the impact of EOs on the intestinal virome. 
The main physiological viral component of the gastrointestinal tract is represented 
by prophages or phages [201]. The bacteriophage component is mainly composed by 
temperate virus of the Caudovirales order, but most of the detected viral sequences 
in human gut virome could not be attributed to known viruses [202] and to date it 
is estimated that the number of virus in human stools is up to 109 per gram [203]. 
Despite it is clear that EOs may impact on the intestinal virome composition by 
modulating all the microbiota components, it could be really difficult to understand 
the direct impact of EOs on the intestinal viruses and the consequences of this 
modulation on the intestinal ecology.
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7. Conclusions
The scientific data present in the literature undoubtedly demonstrate that some 
EOs and some of their components are able to positively modulate the human 
intestinal microbiota, acting in a differentiated way on pathobiontic microorgan-
isms, without altering or even improving the component of microorganisms 
defined as healthier commensals. This selective antimicrobial activity is certain for 
the bacterial component of the intestinal microbiota, conceivable for fungi, but 
at the moment completely unknown for viruses. It is therefore possible to define 
with certainty an eubiotic activity for some EOs and some of their components, 
such as for example geraniol, eugenol, cinnamic aldehyde and limonene, which can 
properly be considered as eubiotics. Finally, it is interesting to note that the antibac-
terial activities of these compounds are always multitarget and that for this reason 
the bacteria are unable to develop resistance. These data associated with the low 
toxicity of these compounds (by oral administration), suggests that these EOs may 
be part of a long-term therapy aimed at restoring an eubiotic and resilient microbial 
ecosystem.
Acknowledgements
The authors thank Dr. Alberto Sardo for illuminating us on the infinite potential 
of essential oils.
Conflicts of interest
The authors declare no conflict of interest.
Funding
This research received no external funding.
Alternative Medicine
28
Author details
Enzo Spisni1*,†, Silvia Turroni2†, Sheri Shahaj3, Renato Spigarelli1, Dario Ayala4  
and Maria Chiara Valerii5
1 Department of Biological, Geological and Environmental Sciences, University of 
Bologna, Via Selmi 3, 40126 Bologna, Italy
2 Department of Pharmacy and Biotechnology, University of Bologna, Via 
Belmeloro 6, 40126 Bologna, Italy
3 Nutrisport Division, Via Leandro Alberti 64, 40100 Bologna, Italy
4 Fitoterapiamedica, located at Artemedica, Via Angera 3, 20125 Milano, Italy
5 Department of Medical and Surgical Sciences, University of Bologna, Via 
Massarenti 9, Bologna 40138, Italy
*Address all correspondence to: enzo.spisni@unibo.it
† ES and ST equally contributed.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
29
Natural Compounds in the Modulation of the Intestinal Microbiota: Implications in Human…
DOI: http://dx.doi.org/10.5772/intechopen.94043
References
[1] Hayashi H, Sakamoto M, Benno Y. 
Phylogenetic analysis of the human 
gut microbiota using 16S rDNA clone 
libraries and strictly anaerobic culture-
based methods. Microbiology and 
Immunology. 2002;46:535-548. DOI: 
10.1111/j.1348-0421.2002.tb02731.x
[2] Phillips ML. Gut reaction: 
Environmental effects on the human 
microbiota. Environmental Health 
Perspectives. 2009;117:A198-A205. DOI: 
10.1289/ehp.117-a198
[3] Young VB. The intestinal microbiota 
in health and disease. Current Opinion 
in Gastroenterology. 2012;28:63-69. 
DOI: 10.1097/MOG.0b013e32834d61e9
[4] Franceschi, C.; Garagnani, P.; 
Parini, P.; Giuliani, C.; Santoro, 
A. Inflammaging: a new immune-
metabolic viewpoint for age-related 
diseases. Nat Rev Endocrinol. 2018; 
14:576-590. doi: 10.1038/s41574-018-
0059-4. doi:10.1038/s41574-018-0059-4.
[5] An R, Wilms E, Masclee AAM, 
Smidt H, Zoetendal EG, Jonkers D. Age-
dependent changes in GI physiology 
and microbiota: Time to reconsider? 
Gut. 2018;67:2213-2222. DOI: 10.1136/
gutjnl-2017-315542
[6] Capurso, G.; Lahner, E. The 
interaction between smoking, alcohol 
and the gut microbiome. Best Pract 
Res Clin Gastroenterol. 2017; 31:579-
588. doi: 10.1016/j.bpg.2017.10.006. 
Epub 2017 Oct 22.). doi:10.1016/j.
bpg.2017.10.006.
[7] Cook MD, Allen JM, Pence BD, 
Wallig MA, Gaskins HR, White BA, et 
al. Exercise and gut immune function: 
Evidence of alterations in colon immune 
cell homeostasis and microbiome 
characteristics with exercise training. 
Immunology and Cell Biology. 
2016;94:158-163. DOI: 10.1038/
icb.2015.108 Epub 2015 Dec 2
[8] Yassour, M.; Vatanen, T.; Siljander, 
H.; Hämäläinen, A.M.; Härkönen, 
T.; Ryhänen, S.J.; Franzosa, E.A.; 
Vlamakis, H.; Huttenhower, C.; 
Gevers, D.; Lander, E.S.; Knip, 
M.; DIABIMMUNE Study Group; 
Xavier, R.J. Natural history of the 
infant gut microbiome and impact 
of antibiotic treatment on bacterial 
strain diversity and stability. Sci Transl 
Med. 2016;8:343ra81. doi: 10.1126/
scitranslmed.aad0917.
[9] Suez, J.; Zmora, N.; Zilberman-
Schapira, G.; Mor, U.; Dori-Bachash, 
M.; Bashiardes, S.; Zur, M.; Regev-
Lehavi, D.; Ben-Zeev Brik, R.; Federici, 
S.; Horn, M.; Cohen, Y.; Moor, A.E.; 
Zeevi, D.; Korem, T.; Kotler, E.; 
Harmelin, A.; Itzkovitz, S.; Maharshak, 
N.; Shibolet, O.; Pevsner-Fischer, M.; 
Shapiro, H.; Sharon, I.; Halpern, Z.; 
Segal, E.; Elinav, E. Post-Antibiotic Gut 
Mucosal Microbiome Reconstitution 
Is Impaired by Probiotics and 
Improved by Autologous FMT. Cell. 
2018a;174:1406-1423.e16. doi: 10.1016/j.
cell.2018.08.047.
[10] Clark CG, Price L, Ahmed R, 
Woodward DL, Melito PL, Rodgers FG, 
et al. Characterization of waterborne 
outbreak-associated campylobacter 
jejuni, Walkerton. Ontario. Emerg 
Infect Dis. 2003;9:1232-1241. DOI: 
10.3201/eid0910.020584
[11] D’Argenio V, Sarnataro D.  
Microbiome influence in the 
pathogenesis of prion and Alzheimer’s 
diseases. International Journal of 
Molecular Sciences. 2019;20:4704. DOI: 
10.3390/ijms20194704
[12] Sun MF, Zhu YL, Zhou ZL, Jia XB, 
Xu YD, Yang Q, et al. Neuroprotective 
effects of fecal microbiota 
transplantation on MPTP-induced 
Parkinson’s disease mice: Gut 
microbiota, glial reaction and TLR4/
TNF-α signaling pathway. Brain, 
Alternative Medicine
30
Behavior, and Immunity. 2018;70:48-60. 
DOI: 10.1016/j.bbi.2018.02.005
[13] Bianchi ME. DAMPs, PAMPs and 
alarmins: All we need to know about 
danger. Journal of Leukocyte Biology. 
2007;81:1-5. DOI: 10.1189/jlb.0306164
[14] Sekirov I, Russell SL, Antunes LC, 
Finlay BB. Gut microbiota in health 
and disease. Physiological Reviews. 
2010;90:859-904. DOI: 10.1152/
physrev.00045.2009
[15] Ni J, Wu GD, Albenberg L, 
Tomov VT. Gut microbiota and IBD: 
Causation or correlation? Nature 
Reviews. Gastroenterology & 
Hepatology. 2017;14:573-584. DOI: 
10.1038/nrgastro.2017.88
[16] Li K, Zhuo C, Teng C, 
Yu S, Wang X, Hu Y, et al. Effects of 
Ganoderma lucidum polysaccharides 
on chronic pancreatitis and intestinal 
microbiota in mice. International 
Journal of Biological Macromolecules. 
2016a;93:904-912. DOI: 10.1016/j.
ijbiomac.2016.09.029
[17] Li KY, Wang JL, Wei JP, 
Gao SY, Zhang YY, Wang LT, et al. Fecal 
microbiota in pouchitis and ulcerative 
colitis. World Journal of 
Gastroenterology. 2016b;22:8929-8939. 
DOI: 10.3748/wjg.v22.i40.8929
[18] Robin L, Dalal MD, Bo Shen MD, 
David A, Schwartz MD. Management 
of Pouchitis and Other Common 
Complications of the pouch. 
Inflammatory Bowel Diseases. 
2018;24:989-996. DOI: 10.1093/ibd/
izy020
[19] Hellström, P.M.; Benno, P. The 
Rome IV: Irritable bowel syndrome - A 
functional disorder. Best Pract Res Clin 
Gastroenterol. 2019;40-41:101634. 
doi:10.1016/j.bpg.2019.101634.
[20] El-Salhy M, Hatlebakk JG, 
Hausken T. Diet in irritable bowel 
syndrome (IBS): Interaction with 
gut microbiota and gut hormones. 
Nutrients. 2019;11:1824. DOI: 10.3390/
nu11081824
[21] Koo HL, Sabounchi S, Huang DB, 
DuPont HL. Rifaximin Therapy of 
Irritable Bowel Syndrome Clin Med 
Insights Gastroenterol. 2012;5:31-41. 
DOI: 10.4137/CGast.S7382
[22] Akobeng AK, Singh P, Kumar M, 
Al Khodor S. Role of the gut microbiota 
in the pathogenesis of coeliac disease 
and potential therapeutic implications. 
European Journal of Nutrition. 2020. 
DOI: 10.1007/s00394-020-02324-y
[23] Fröhlich E, Wahl R. Microbiota 
and thyroid interaction in health and 
disease. Trends in Endocrinology and 
Metabolism. 2019;30:479-490. DOI: 
10.1016/j.tem.2019.05.008
[24] Zhao F, Feng J, Li J, Zhao L, Liu Y, 
Chen H, et al. Alterations of the gut 
microbiota in Hashimoto’s thyroiditis 
patients. Thyroid. 2018;28(2):175-186. 
DOI: 10.1089/thy.2017.0395
[25] Kiseleva EP, Mikhailopulo KI, 
Sviridov OV, Novik GI, Knirel YA, 
Szwajcer Dey E. The role of components 
of Bifidobacterium and lactobacillus in 
pathogenesis and serologic diagnosis 
of autoimmune thyroid diseases. Benef 
Microbes. 2011;2:139-154. DOI: 10.3920/
BM2010.0011
[26] Köhling HL, Plummer SF, 
Marchesi JR, Davidge KS, Ludgate M. 
The microbiota and autoimmunity: 
Their role in thyroid autoimmune 
diseases. Clinical Immunology. 
2017;183:63-74. DOI: 10.1016/j.
clim.2017.07.001
[27] Ishaq HM, Mohammad IS, 
Shahzad M, Ma C, Raza MA, Wu X, 
et al. Molecular alteration analysis of 
human gut microbial composition in 
Graves’ disease patients. International 
Journal of Biological Sciences. 
31
Natural Compounds in the Modulation of the Intestinal Microbiota: Implications in Human…
DOI: http://dx.doi.org/10.5772/intechopen.94043
2018;14:1558-1570. DOI: 10.7150/
ijbs.24151
[28] Tilg H, Zmora N, Adolph TE, 
Elinav E. The intestinal microbiota 
fuelling metabolic inflammation. Nature 
Reviews. Immunology. 2020;20:40-54. 
DOI: 10.1038/s41577-019-0198-4
[29] Bäckhed F, Ding H, Wang T, 
Hooper LV, Koh GY, Nagy A, et al. The 
gut microbiota as an environmental 
factor that regulates fat storage. 
Proceedings of the National Academy 
of Sciences of the United States of 
America. 2004;101:15718-15723. DOI: 
10.1073/pnas.0407076101
[30] Cotillard, A.; Kennedy, S.P.; Kong, 
L.C.; Prifti, E.; Pons, N.; Le Chatelier, 
E.; Almeida, M.; Quinquis, B.; Levenez, 
F.; Galleron, N.; Gougis, S.; Rizkalla, S.; 
Batto, J.M.; Renault, P.; ANR MicroObes 
consortium; Doré, J.; Zucker, J.D.; 
Clément, K.; Ehrlich, S.D. Dietary 
intervention impact on gut microbial 
gene richness [published correction 
appears in Nature. 2013; 502: 580. 
Nature. 2013;500:585-588. doi:10.1038/
nature12480.
[31] Qin, J.; Li, Y.; Cai, Z.; Li, S.; Zhu, J.; 
Zhang, F.; Liang, S.; Zhang, W.; Guan, 
Y.; Shen, D.; Peng, Y.; Zhang, D.; Jie, Z.; 
Wu, W.; Qin, Y.; Xue, W.; Li, J.; Han, L.; 
Lu, D.; Wu, P.; Dai Y.; Sun, X.; Li, Z.; 
Tang, A.; Zhong, S.; Li, X.; Chen, W.; 
Xu, R.; Wang, M.; Feng, Q.; Gong, M.; 
Yu, J.; Zhang, Y.; Zhang, M.; Hansen, 
T.; Sanchez, G.; Raes, J.; Falony, G.; 
Okuda, S.; Almeida, M.; LeChatelier, E.; 
Renault, P.; Pons, N.; Batto, J.M.; Zhang, 
Z.; Chen, H.; Yang, R.; Zheng, W.; Li, 
S.; Yang, H.; Wang, J.; Ehrlich, S.D.; 
Nielsen, R.; Pedersen, O.; Kristiansen, 
K.; Wang, J. A metagenome-wide 
association study of gut microbiota in 
type 2 diabetes. Nature. 2012;490:55-60. 
doi:10.1038/nature11450.
[32] Vrieze, A.; Van Nood, E.; 
Holleman, F.; Salojärvi, J.; Kootte, 
R.S.; Bartelsman, J.F.; Dallinga-Thie, 
G.M.; Ackermans, M.T.; Serlie, M.J.; 
Oozeer, R.; Derrien, M.; Druesne, A.; 
Van Hylckama Vlieg, J.E.; Bloks, V.W.; 
Groen, A.K.; Heilig, H.G.; Zoetendal, 
E.G.; Stroes, E.S.; de Vos, W.M.; 
Hoekstra, J.B.; Nieuwdorp, M. Transfer 
of intestinal microbiota from lean 
donors increases insulin sensitivity in 
individuals with metabolic syndrome 
Gastroenterology. 2012;143:913-6.e7. 
doi:10.1053/j.gastro.2012.06.031.
[33] Houghton D, Hardy T, Stewart C, 
Errington L, Day CP, Trenell MI, et 
al. Systematic review assessing the 
effectiveness of dietary intervention 
on gut microbiota in adults with type 2 
diabetes. Diabetologia. 2018;61:1700-
1711. DOI: 10.1007/s00125-018-4632-0
[34] Loomba R, Seguritan V, Li W, 
Long T, Klitgord N, Bhatt A, et al. 
Gut Microbiome-Based Metagenomic 
Signature for Non-invasive Detection 
of Advanced Fibrosis in Human 
Nonalcoholic Fatty Liver Disease 
Cell Metab. 2017;25:1054-1062. DOI: 
10.1016/j.cmet.2017.04.001
[35] Li J, Zhao F, Wang Y, Chen J, Tao J, 
Tian G, et al. Gut microbiota dysbiosis 
contributes to the development of 
hypertension. Microbiome. 2017;5:14. 
DOI: 10.1186/s40168-016-0222-x
[36] Parfrey LW, Walters WA, Lauber CL, 
Clemente JC, Berg-Lyons D, Teiling C, et 
al. Communities of microbial eukaryotes 
in the mammalian gut within the 
context of environmental eukaryotic 
diversity. Frontiers in Microbiology. 
2014;5:298. DOI: 10.3389/
fmicb.2014.00298
[37] Shang F, Liu H. Fusobacterium 
nucleatum and colorectal cancer: A 
review. World J Gastrointest Oncol. 
2018;10:71-81. DOI: 10.4251/wjgo.v10.
i3.71
[38] Ma, C.; Han, M.; Heinrich, B.; Fu, 
Q.; Zhang, Q.; Sandhu, M.; Agdashian, 
D.; Terabe, M.; Berzofsky, J.A.; Fako, V. 
Alternative Medicine
32
Gut microbiome–mediated bile acid 
metabolism regulates liver cancer via 
NKT cells. Science. 2018;360:eaan5931. 
doi:10.1126/science.aan5931.
[39] Dutta, D.; Lim, S.H. Bidirectional 
interaction between intestinal 
microbiome and cancer: opportunities 
for therapeutic interventions. 
Biomark Res 2020; 8: 31 (). https://doi.
org/10.1186/s40364-020-00211-6
[40] Zhuang H, Wang Y, 
Zhang Y, Zhao M, Liang G, Zhang M, 
et al. Dysbiosis of the gut microbiome 
in lung cancer. Frontiers in Cellular and 
Infection Microbiology. 2019;9:112. 
DOI: 10.3389/fcimb.2019.00112
[41] Zhang W, Zhao S, Luo J, Dong X, 
Hao Y, Li H, et al. Alterations of fecal 
bacterial communities in patients 
with lung cancer. American Journal of 
Translational Research. 2018a;10:3171-
3185. PMID: 30416659
[42] Zhang Y, Zhou S, Zhou Y, 
Yu L, Zhang L, Wang Y. Altered gut 
microbiome composition in children 
with refractory epilepsy after 
ketogenic diet. Epilepsy Research. 
2018b;145:163-168. DOI: 10.1016/j.
eplepsyres.2018.06.015
[43] Ouabbou S, He Y, Butler K, 
Tsuang M. Inflammation in mental 
disorders: Is the microbiota the 
missing link? Neuroscience Bulletin. 
2020;36:1071-1084. DOI: 10.1007/
s12264-020-00535-1
[44] Sundquist K, Li X, 
Hemminki K, Sundquist J. Subsequent 
risk of hospitalization for 
neuropsychiatric disorders in patients 
with rheumatic diseases: A nationwide 
study from Sweden. Archives of General 
Psychiatry. 2008;65:501-507
[45] Benros ME, Nielsen PR, 
Nordentoft M, Eaton WW, Dalton SO, 
Mortensen PB. Autoimmune diseases 
and severe infections as risk factors 
for schizophrenia: A 30-year 
population-based register study. 
The American Journal of Psychiatry. 
2011;168:1303-1310. DOI: 10.1176/appi.
ajp.2011.11030516
[46] Benros ME, Eaton WW, 
Mortensen PB. The epidemiologic 
evidence linking autoimmune diseases 
and psychosis. Biological Psychiatry. 
2014;75:300-306. DOI: 10.1016/j.
biopsych.2013.09.023
[47] Cascella NG, Kryszak D, Bhatti B, 
Gregory P, Kelly DL, Mc Evoy JP, et al. 
Prevalence of celiac disease and gluten 
sensitivity in the United States clinical 
antipsychotic trials of intervention 
effectiveness study population. 
Schizophrenia Bulletin. 2011;37:94-100. 
DOI: 10.1093/schbul/sbp055
[48] Sudo N, Chida Y, Aiba Y,  
Sonoda J, Oyama N, Yu XN, et al. 
Postnatal microbial colonization 
programs the hypothalamicpituitary- 
adrenal system for stress response in 
mice. Journal of Physiology (London). 
2004;558:263-275. DOI: 10.1113/
jphysiol.2004.063388
[49] Fang, P.; Kazmi, S.A.; Jameson, 
K.G.; Hsiao, E.Y. The Microbiome as a 
Modifier of Neurodegenerative Disease 
Risk. Cell Host Microbe. 2020;28:201-
222. doi:10.1016/j.chom.2020.06.008. 
doi:10.1016/j.chom.2020.06.008.
[50] Bedarf JR, Hildebrand F, Coelho LP, 
Sunagawa S, Bahram M, Goeser F, et al. 
Functional implications of microbial 
and viral gut metagenome changes in 
early stage L-DOPA-naïve Parkinson’s 
disease patients. Genome Medicine. 
2017;9:39. https://doi.org/10.1186/
s13073-017-0428-y;
[51] Jiang C, Li G, Huang P, 
Liu Z, Zhao B. The gut microbiota and 
Alzheimer’s disease. Journal of 
Alzheimer’s Disease. 2017;58:1-15. DOI: 
10.3233/JAD-161141
33
Natural Compounds in the Modulation of the Intestinal Microbiota: Implications in Human…
DOI: http://dx.doi.org/10.5772/intechopen.94043
[52] Metchnikoff E. The Prolongation 
of Life: Optimistic Studies. New York & 
London: G.P. Putnam’s Sons; 1908. pp. 
161-183
[53] Ciorba MA. A gastroenterologist’s 
guide to probiotics. Clinical 
Gastroenterology and Hepatology. 
2012;10:960-968. DOI: 10.1016/j.
cgh.2012.03.024
[54] Zmora N, Suez J, Elinav E. You 
are what you eat: Diet, health and 
the gut microbiota. Nature Reviews. 
Gastroenterology & Hepatology. 
2019;16:35-56. DOI: 10.1038/
s41575-018-0061-2
[55] Hill C, Guarner F, Reid G, 
Gibson GR, Merenstein DJ, Pot B, et 
al. Expert consensus document. The 
international scientific Association 
for Probiotics and Prebiotics 
consensus statement on the scope and 
appropriate use of the term probiotic. 
Nature Reviews. Gastroenterology & 
Hepatology. 2014;11:506-514. DOI: 
10.1038/nrgastro.2014.66
[56] Suez J, Zmora N, Segal E, Elinav E. 
The pros, cons, and many unknowns 
of probiotics. Nature Medicine. 
2019;25:716-729. DOI: 10.1038/
s41591-019-0439-x
[57] Deshpande G, Athalye-Jape G, 
Patole S. Para-probiotics for preterm 
neonates-the next frontier. Nutrients. 
2018;10:871. DOI: 10.3390/nu10070871
[58] Wegh CAM, Geerlings SY, Knol J, 
Roeselers G, Belzer C. Postbiotics and 
their potential applications in 
early life nutrition and beyond. 
International Journal of Molecular 
Sciences. 2019;20:4673. DOI: 10.3390/
ijms20194673
[59] Derrien M, van Hylckama Vlieg JE. 
Fate, activity, and impact of ingested 
bacteria within the human gut 
microbiota. Trends in Microbiology. 
2015;23:354-366. DOI: 10.1016/j.
tim.2015.03.002
[60] Khalesi S, Bellissimo N,  
Vandelanotte C, Williams S,  
Stanley D, Irwin C. A review of 
probiotic supplementation in healthy 
adults: Helpful or hype? European 
Journal of Clinical Nutrition. 
2019;73:24-37. DOI: 10.1038/
s41430-018-0135-9
[61] Aceti A, Beghetti I, Maggio L, 
Martini S, Faldella G, Corvaglia L. Filling 
the gaps: Current research directions for 
a rational use of probiotics in preterm 
infants. Nutrients. 2018;10:1472. DOI: 
10.3390/nu10101472
[62] Sniffen, J.C.; McFarland, L.V.;  
Evans, C.T.; Goldstein, E.J.C. Choosing 
an appropriate probiotic product 
for your patient: An evidence-
based practical guide. PLoS One. 
2018;13:e0209205. doi:10.1371/journal.
pone.0209205. doi:10.1371/journal.
pone.0209205.
[63] Suez J, Zmora N,  
Elinav E. Probiotics in the next-
generation sequencing era. Gut 
Microbes. 2020;11:77-93. DOI: 
10.1080/19490976.2019.1586039
[64] Zmora, N.; Zilberman-Schapira, 
G.; Suez, J.; Mor, U.; Dori-Bachash, 
M.; Bashiardes, S.; Kotler, E.; Zur, M.; 
Regev-Lehavi, D.; Brik, R.B.; Federici, 
S.; Cohen, Y.; Linevsky, R.; Rothschild, 
D.; Moor, A.E.; Ben-Moshe, S.; 
Harmelin, A.; Itzkovitz, S.; Maharshak, 
N.; Shibolet, O.; Shapiro, H.; Pevsner-
Fischer, M.; Sharon, I.; Halpern, Z.; 
Segal, E.; Elinav, E. Personalized Gut 
Mucosal Colonization Resistance to 
Empiric Probiotics Is Associated with 
Unique Host and Microbiome Features. 
Cell. 2018; 174:1388-1405. doi: 10.1016/j.
cell.2018.08.041.
[65] O’Toole PW, Marchesi JR, 
Hill C. Next-generation probiotics: 
The spectrum from probiotics to live 
biotherapeutics. Nature Microbiology. 
2017;2:17057. DOI: 10.1038/
nmicrobiol.2017.57
Alternative Medicine
34
[66] Martín R, Bermúdez-Humarán LG, 
Langella P. Searching for the bacterial 
effector: The example of the multi-
skilled commensal bacterium 
Faecalibacterium prausnitzii. Frontiers 
in Microbiology. 2018;9:346. DOI: 
10.3389/fmicb.2018.00346
[67] Cani PD, de Vos WM. Next-
generation beneficial microbes: The case 
of Akkermansia muciniphila. Frontiers 
in Microbiology. 2017;8:1765. DOI: 
10.3389/fmicb.2017.01765
[68] Depommier C, Everard A, Druart C, 
Plovier H, Van Hul M, Vieira-Silva S, et 
al. Supplementation with Akkermansia 
muciniphila in overweight and obese 
human volunteers: A proof-of-concept 
exploratory study. Nature Medicine. 
2019;25:1096-1103. DOI: 10.1038/
s41591-019-0495-2
[69] Motta, J.P.; Bermúdez-Humarán, 
L.G.; Deraison, C.; Martin, L.; Rolland, 
C.; Rousset, P.; Boue, J.; Dietrich, 
G.; Chapman, K.; Kharrat, P.; Vinel, 
J.P.; Alric, L.; Mas, E.; Sallenave, 
J.M.; Langella, P.; Vergnolle, N. 
Food-grade bacteria expressing elafin 
protect against inflammation and 
restore colon homeostasis. Sci Transl 
Med. 2012;4:158ra144. doi: 10.1126/
scitranslmed.3004212.
[70] Caluwaerts S, Vandenbroucke K, 
Steidler L, Neirynck S, Vanhoenacker P, 
Corveleyn S, et al. AG013, a mouth 
rinse formulation of Lactococcus 
lactis secreting human trefoil factor 
1, provides a safe and efficacious 
therapeutic tool for treating 
oral mucositis. Oral Oncology. 
2010;46:564-570. DOI: 10.1016/j.
oraloncology.2010.04.008
[71] Frossard CP, Steidler L, 
Eigenmann PA. Oral administration 
of an IL-10-secreting Lactococcus 
lactis strain prevents food-induced IgE 
sensitization. The Journal of Allergy and 
Clinical Immunology. 2007;119:952-959. 
DOI: 10.1016/j.jaci.2006.12.615
[72] Farrar, MD.; Whitehead, 
T.R.; Lan, J.; Dilger, P.; Thorpe, 
R.; Holland, K.T.; Carding, S.R. 
Engineering of the gut commensal 
bacterium Bacteroides ovatus to 
produce and secrete biologically 
active murine interleukin-2 in 
response to xylan. Journal of Applied 
Microbiology 2005;98:1191-1197. doi: 
10.1111/j.1365-2672.2005.02565.x.
[73] Hamady ZZ, Scott N, Farrar MD,  
Wadhwa M, Dilger P, Whitehead TR,  
et al. Treatment of colitis with a 
commensal gut bacterium engineered 
to secrete human TGF-β1 under the 
control of dietary xylan 1. Inflammatory 
Bowel Diseases. 2011;17:1925-1935. DOI: 
10.1002/ibd.21565
[74] Ho CL, Tan HQ, Chua KJ, Kang A, 
Lim KH, Ling KL, et al. Engineered 
commensal microbes for diet-mediated 
colorectal-cancer chemoprevention. 
Nature Biomedical Engineering. 
2018;2:27-37. DOI: 10.1038/
s41551-017-0181-y
[75] Kelly D, King T, Aminov R. 
Importance of microbial colonization of 
the gut in early life to the development 
of immunity. Mutation Research. 
2007;622:58-69. DOI: 10.1016/j.
mrfmmm.2007.03.011
[76] Barrett MJ, Donoghue V,  
Mooney EE, Slevin M, Persaud T, 
Twomey E, et al. Isolated acute non-
cystic white matter injury in term 
infants presenting with neonatal 
encephalopathy. Archives of Disease in 
Childhood. Fetal and Neonatal Edition. 
2013;98:F158-F160. DOI: 10.1136/
archdischild-2011-301505
[77] Payne AN, Chassard C, Lacroix C. 
Gut microbial adaptation to dietary 
consumption of fructose, artificial 
sweeteners and sugar alcohols: 
Implications for host-microbe 
interactions contributing to obesity. 
Obesity Reviews. 2012;13:799-809. DOI: 
10.1111/j.1467-789X.2012.01009.x
35
Natural Compounds in the Modulation of the Intestinal Microbiota: Implications in Human…
DOI: http://dx.doi.org/10.5772/intechopen.94043
[78] Lee HC, Jenner AM, Low CS, 
Lee YK. Effect of tea phenolics and their 
aromatic fecal bacterial metabolites 
on intestinal microbiota. Research in 
Microbiology. 2006;157:876-884. DOI: 
10.1016/j.resmic.2006.07.004
[79] Caesar R, Tremaroli V,  
Kovatcheva-Datchary P, Cani PD, 
Bäckhed F. Crosstalk between gut 
microbiota and dietary lipids aggravates 
WAT inflammation through TLR 
signaling. Cell Metabolism. 2015;22:658-
668. DOI: 10.1016/j.cmet.2015.07.026
[80] Martinez-Guryn K, Hubert N, 
Frazier K, Urlass S, Musch MW, Ojeda P, 
et al. Small intestine microbiota regulate 
host digestive and absorptive adaptive 
responses to dietary lipids. Cell Host 
& Microbe. 2018;23:458-469. DOI: 
10.1016/j.chom.2018.03.011
[81] Illiano P, Brambilla R, Parolini C. 
The mutual interplay of gut microbiota, 
diet and human disease. The FEBS 
Journal. 2020;287:833-855. DOI: 10.1111/
febs.15217
[82] Kim M, Qie Y, Park J, Kim CH. Gut 
microbial metabolites fuel host antibody 
responses. Cell Host & Microbe. 
2016;20:202-214. DOI: 10.1016/j.
chom.2016.07.001
[83] Whiting CV, Bland PW, Tarlton JF. 
Dietary n-3 polyunsaturated fatty 
acids reduce disease and colonic 
proinflammatory cytokines in a mouse 
model of colitis. Inflammatory Bowel 
Diseases. 2005;11:340-349. DOI: 
10.1097/01.mib.0000164016.98913.7c
[84] Watson H, Mitra S, Croden FC, 
Taylor M, Wood HM, Perry SL, et al. 
A randomised trial of the effect of 
omega-3 polyunsaturated fatty acid 
supplements on the human intestinal 
microbiota. Gut. 2018;67:1974-1983. 
DOI: 10.1136/gutjnl-2017-314968
[85] Andersen AD, Mølbak L, 
Michaelsen KF, Lauritzen L. Molecular 
fingerprints of the human fecal 
microbiota from 9 to 18 months old and 
the effect of fish oil supplementation. 
Journal of Pediatric Gastroenterology 
and Nutrition. 2011;53:303-309. DOI: 
10.1097/MPG.0b013e31821d298f
[86] Provensi G, Schmidt SD, 
Boehme M, Bastiaanssen T, Rani B, 
Costa A, et al. Preventing adolescent 
stress-induced cognitive and 
microbiome changes by diet. 
Proceedings of the National Academy 
of Sciences of the United States of 
America. 2019;116:9644-9651. DOI: 
10.1073/pnas.1820832116
[87] Wright SL, Kelly FJ. Plastic 
and human health: A micro issue? 
Environmental Science & Technology. 
2017;51:6634-6647. DOI: 10.1021/acs.
est.7b00423
[88] Hentges DJ, Maier BR, Burton GC, 
Flynn MA, Tsutakawa RK. Effect of 
a high-beef diet on the fecal bacterial 
flora of humans. Cancer Research. 
1977;37:568-571
[89] Blachier F, Beaumont M,  
Portune KJ, Steuer N, Lan A, 
Audebert M, et al. High-protein diets 
for weight management: Interactions 
with the intestinal microbiota and 
consequences for gut health. A position 
paper by the my new gut study group. 
Clinical Nutrition. 2019;38:1012-1022. 
DOI: 10.1016/j.clnu.2018.09.016
[90] Kim CH, Park J, Kim M. Gut 
microbiota-derived short-chain fatty 
acids, T cells, and inflammation. 
Immune Netw. 2014;14:277-288. DOI: 
10.4110/in.2014.14.6.277
[91] Russell WR, Gratz SW, Duncan SH, 
Holtrop G, Ince J, Scobbie L, et al. 
High-protein, reduced-carbohydrate 
weight-loss diets promote metabolite 
profiles likely to be detrimental to 
colonic health. Clinical Nutrition. 
2011;93:1062-1072. DOI: 10.3945/
ajcn.110.002188
Alternative Medicine
36
[92] De Filippis F, Pellegrini N, 
Vannini L, Jeffery IB, La Storia A, 
Laghi L, et al. High-level adherence to a 
Mediterranean diet beneficially impacts 
the gut microbiota and associated 
metabolome. Gut. 2016;65:1812-1821. 
DOI: 10.1136/gutjnl-2015-309957
[93] Yang, H.; Chunying, T. Inonotus 
obliquus polysaccharide regulates gut 
microbiota of chronic pancreatitis in 
mice. AMB Express. 2017; 7: 39. doi: 
10.1186/s13568-017-0341-1
[94] Stephen AM, Cummings JH. 
Mechanism of action of dietary fibre in 
the human colon. Nature. 1980;284:283-
284. DOI: 10.1038/284283a0
[95] Pandey KR, Naik SR, Vakil BV. 
Probiotics, prebiotics and synbiotics- a 
review. Journal of Food Science and 
Technology. 2015;52:7577-7587. DOI: 
10.1007/s13197-015-1921-1
[96] Keim NL, Martin RJ. Dietary whole 
grain–microbiota interactions: Insights 
into mechanisms for human health. 
Advances in Nutrition. 2014;5:556-557. 
DOI: 10.3945/an.114.006536
[97] Eid N, Enani S, Walton G, 
Corona G, Costabile A, Gibson G, et 
al. The impact of date palm fruits and 
their component polyphenols, on gut 
microbial ecology, bacterial metabolites 
and colon cancer cell proliferation. J 
Nutr Sci. 2014;3:e46. DOI: 10.1017/
jns.2014.16
[98] Francavilla R, Calasso M,  
Calace L, Siragusa S, Ndagijimana M, 
Vernocchi P, et al. De Angelis, M. 
Effect of lactose on gut microbiota 
and metabolome of infants with 
cow’s milk allergy Pediatr Allergy 
Immunol. 2012;23:420-427. DOI: 
10.1111/j.1399-3038.2012.01286.x
[99] Rowland I, Gibson G, Heinken A, 
Scott K, Swann J, Thiele I, et al. Gut 
microbiota Funct.s: Metab. Of Nutr. 
And other food components. European 
Journal of Nutrition. 2018;57:1-24. DOI: 
10.1007/s00394-017-1445-8
[100] Lee H, Ko G. New perspectives 
regarding the antiviral effect of 
vitamin a on norovirus using 
modulation of gut microbiota. Gut 
Microbes. 2017;8:616-620. DOI: 
10.1080/19490976.2017.1353842
[101] Liu J, Liu X, Xiong XQ, Yang T, 
Cui T, Hou NL, et al. Effect of vitamin 
a supplementation on gut microbiota in 
children with autism spectrum disorders 
- a pilot study. BMC Microbiology. 
2017;17:204. DOI: 10.1186/
s12866-017-1096-1
[102] Huda MN, Ahmad SM, 
Kalanetra KM, Taft DH, Alam MJ, 
Khanam A, et al. Neonatal vitamin a 
supplementation and vitamin a status 
are associated with gut microbiome 
composition in bangladeshi infants in 
early infancy and at 2 years of age. The 
Journal of Nutrition. 2019;149:1075-
1088. DOI: 10.1093/jn/nxz034
[103] Xu J, Xu C, Chen X, Cai X,  
Yang S, Sheng Y, et al. Regulation  
of an antioxidant blend on intestinal 
redox status and major microbiota 
in early weaned piglets. Nutrition. 
2014;30:584-589. DOI: 10.1016/j.
nut.2013.10.018
[104] Bertone-Johnson ER, Powers SI, 
Spangler L, Brunner RL, Michael YL, 
Larson JC, et al. Vitamin D intake from 
foods and supplements and depressive 
symptoms in a diverse population 
of older women. Clinical Nutrition. 
2011;94:1104-1112. DOI: 10.3945/
ajcn.111.017384
[105] Stacchiotti V, Rezzi S, 
Eggersdorfer M, Galli F. Metabolic 
and functional interplay between gut 
microbiota and fat-soluble vitamins. 
Critical Reviews in Food Science 
and Nutrition. 2020:1-22. DOI: 
10.1080/10408398.2020.1793728
37
Natural Compounds in the Modulation of the Intestinal Microbiota: Implications in Human…
DOI: http://dx.doi.org/10.5772/intechopen.94043
[106] Sperandio V. Take your pick: 
Vitamins and microbiota facilitate 
pathogen clearance. Cell Host & 
Microbe. 2017;21:130-131. DOI: 
10.1016/j.chom.2017.01.013
[107] Thiennimitr P, Winter SE,  
Winter MG, Xavier MN, Tolstikov V,  
Huseby DL, et al. Intestinal 
inflammation allows salmonella to 
use ethanolamine to compete with the 
microbiota. Proceedings of the National 
Academy of Sciences of the United 
States of America. 2011;108:17480-
17485. DOI: 10.1073/pnas.1107857108
[108] Bialonska D, Ramnani P,  
Kasimsetty SG, Muntha KR, 
Gibson GR, Ferreira D. The influence 
of pomegranate by-product and 
punicalagins on selected groups 
of human intestinal microbiota. 
International Journal of Food 
Microbiology. 2010;140:175-182. DOI: 
10.1016/j.ijfoodmicro.2010.03.038
[109] Martin FP, Montoliu I,  
Nagy K, Moco S, Collino S, Guy P,  
et al. Specific dietary preferences 
are linked to differing gut microbial 
metabolic activity in response to dark 
chocolate intake. Proteome Research. 
2012;11:6252-6263. DOI: 10.1021/
pr300915z
[110] Tzounis X, Vulevic J, Kuhnle GG, 
George T, Leonczak J, Gibson GR, et al. 
Flavanol monomer-induced changes to 
the human faecal microflora. The British 
Journal of Nutrition. 2008;99:782-792. 
DOI: 10.1017/S0007114507853384
[111] Chassaing B, Koren O, 
Goodrich JK, Poole AC, Srinivasan S, 
Ley RE, et al. Dietary emulsifiers impact 
the mouse gut microbiota promoting 
colitis and metabolic. Nature. 
2015;519:92-96. DOI: 10.1038/
nature14232
[112] Suez J, Korem T, Zeevi D, 
Zilberman-Schapira G, Thaiss CA, 
Maza O, et al. Artificial sweeteners 
induce glucose intolerance by 
altering the gut microbiota. Nature. 
2014;514:181-186. DOI: 10.1038/
nature13793
[113] Dunn KA, Moore-Connors J, 
MacIntyre B, Stadnyk A, Thomas NA, 
Noble A, et al. The gut microbiome 
of pediatric Crohn’s disease patients 
differs from healthy controls in genes 
that can influence the balance between 
a healthy and dysregulated immune 
response. Inflammatory Bowel Diseases. 
2016;22:2607-2618. DOI: 10.1097/
MIB.0000000000000949
[114] Drasar BS, Crowther JS, Goddard P, 
Hawksworth G, Hill MJ, Peach S, et al. 
The relation between diet and the gut 
microflora in man. The Proceedings of 
the Nutrition Society. 1973;32:49-52. 
DOI: 10.1079/pns19730014
[115] Tagliabue A, Ferraris C, Uggeri F, 
Trentani C, Bertoli S, de Giorgis V,  
et al. Short-term impact of a classical 
ketogenic diet on gut microbiota 
in GLUT1 deficiency syndrome: A 
3-month prospective observational 
study. Clin Nutr ESPEN. 2017;17:33-37. 
DOI: 10.1016/j.clnesp.2016.11.003
[116] Salas-Salvadó J, Bulló M, Estruch R, 
Ros E, Covas MI, Ibarrola-Jurado N, 
et al. Prevention of diabetes with 
Mediterranean diets: a subgroup 
analysis of a randomized trial Ann 
Intern Med. 2014;160:1-10. DOI: 
10.7326/M13-1725
[117] Wu GD, Compher C, Chen EZ, 
Smith SA, Shah RD, Bittinger K, et al. 
Comparative metabolomics in vegans 
and omnivores reveal constraints 
on diet-dependent gut microbiota 
metabolite production. Gut. 2016;65:63-
72. DOI: 10.1136/gutjnl-2014-308209
[118] van Duynhoven J, Vaughan EE, 
Jacobs DM, Kemperman RA, van 
Velzen EJ, Gross G, et al. Metabolic 
fate of polyphenols in the human 
superorganism. Proceedings of 
Alternative Medicine
38
the National Academy of Sciences 
of the United States of America. 
2011;108(Suppl 1):4531-4538. DOI: 
10.1073/pnas.1000098107
[119] Velma T.E. Aho, Pedro A.B. 
Pereira, Sari Voutilainen, Lars Paulin, 
Eero Pekkonen, Petri Auvinen, 
Filip Scheperjans. Gut microbiota in 
Parkinson’s disease: Temporal stability 
and relations to disease progression. 
The Lancet, 2019; 44: 691-707. doi: 
org/10.1016/j.ebiom.2019.05.064.
[120] Lopez-Legarrea P, Fuller NR, 
Zulet MA, Martinez JA, Caterson ID. The 
influence of Mediterranean, carbohydrate 
and high protein diets on gut microbiota 
composition in the treatment of obesity 
and associated inflammatory state. Asia 
Pacific Journal of Clinical Nutrition. 
2014;23:360-368. DOI: 10.6133/
apjcn.2014.23.3.16
[121] Ayala, D.; Cerioli, G. Clinical 
Phytotherapy: The P.N.E.I.S.E Paradigm 
as Diagnostic and Therapeutic 
Guideline. Human as Dynamic And 
Interactive Psycho-Neuro-Endocrine-
Immune-Somatic–Environmental Unity. 
Piante Medicinali Volume 15, 2016.
[122] Friedman M. Chemistry, nutrition, 
and health-promoting properties of 
Hericium erinaceus (Lion’s mane) 
mushroom fruiting bodies and mycelia 
and their bioactive compounds. Journal 
of Agricultural and Food Chemistry. 
2015;63:7108-7123. DOI: 10.1021/acs.
jafc.5b02914
[123] Khan MA, Tania M, Liu R, 
Rahman MM. Hericium erinaceus: An 
edible mushroom with medicinal values. 
J Complement Integr Med. 2013;10. 
DOI: 10.1515/jcim-2013-0001
[124] Thongbai B, Rapior S, Hyde KD, 
Wittstein K, Stadler M. Hericium 
erinaceus, an amazing medicinal 
mushroom. Mycological Progress. 
2015;14:1-23. DOI: 10.1007/
s11557-015-1105-4
[125] He W, Rahimnejad S, 
Wang L, Song K, Lu K, Zhang C. Effects 
of organic acids and essential oils 
blend on growth, gut microbiota, 
immune response and disease 
resistance of Pacific white shrimp 
(Litopenaeus vannamei) against Vibrio 
parahaemolyticus. Fish & Shellfish 
Immunology. 2017a;70:164-173. DOI: 
10.1016/j.fsi.2017.09.007
[126] He X, Wang X, Fang JC,  
Chang Y, Ning N, Guo H, et al. 
Structures, biological activities, 
and industrial applications of the 
polysaccharides from Hericium 
erinaceus (Lion’s mane) mushroom: 
A review. International Journal of 
Biological Macromolecules. 2017b;97. 
DOI: 10.1016/j.ijbiomac.2017.01.040
[127] Sheng X, Yan J, Meng Y, Kang Y, 
Han Z, Tai G, et al. Immunomodulatory 
effects of Hericium erinaceus derived 
polysaccharides are mediated by 
intestinal immunology. Food & 
Function. 2017;8:1020-1027. DOI: 
10.1039/c7fo00071e
[128] Diling C, Chaoqun Z, 
Jian Y, Jian L, Jiyan S, Yizhen X, et al. 
Immunomodulatory activities of a 
fungal protein extracted from Hericium 
erinaceus through regulating the gut 
microbiota. Frontiers in Immunology. 
2017a;8:666. DOI: 10.3389/
fimmu.2017.00666
[129] Diling, C.; Xin, Y.; Chaoqun, Z.; 
Jian, Y.; Xiaocui, T.; Jun, C.; Ou, S.; 
Yizhen, X. “Extracts from Hericium 
erinaceus relieve inflammatory bowel 
disease by regulating immunity 
and gut microbiota.” Oncotarget. 
2017b; 8:85838-85857. doi:10.18632/
oncotarget.20689.
[130] Shao, S.; Wang, D.; Zheng, W.; Li, 
X.; Zhang, H.; Zhao, D.; Wang, M. “A 
unique polysaccharide from Hericium 
erinaceus mycelium ameliorates acetic 
acid-induced ulcerative colitis rats by 
modulating the composition of the 
39
Natural Compounds in the Modulation of the Intestinal Microbiota: Implications in Human…
DOI: http://dx.doi.org/10.5772/intechopen.94043
gut microbiota, short chain fatty acids 
levels and GPR41/43 respectors.”.Int 
Immunopharmacol. 2019; 71:411-422. 
doi:10.1016/j.intimp.2019.02.038.
[131] Ren Y, Geng Y, Du Y, Li W, 
Lu ZM, Xu HY, et al. Polysaccharide of 
Hericium erinaceus attenuates colitis 
in C57BL/6 mice via regulation of 
oxidative stress, inflammation-related 
signaling pathways and modulating the 
composition of the gut microbiota. The 
Journal of Nutritional Biochemistry. 
2018;57:67-76. DOI: 10.1016/j.
jnutbio.2018.03.005
[132] Balandaykin ME, Zmitrovich IV. 
Review on Chaga medicinal mushroom, 
Inonotus obliquus (higher 
basidiomycetes): Realm of medicinal 
applications and approaches on 
estimating its resource potential. Int J 
Med Mushrooms. 2015;17:95-104. DOI: 
10.1615/intjmedmushrooms.v17.i2.10
[133] Shashkina MY, Shashkin PN,  
Sergeev AV. Chemical and 
Medicobiological properties of Chaga 
(review). Pharmaceutical Chemistry 
Journal. 2006;40:560-568 https://doi.
org/10.1007/s11094-006-0194-4
[134] Chen YF, Zheng JJ, Qu C, Xiao Y, 
Li FF, Jin QX, et al. Inonotus obliquus 
polysaccharide ameliorates dextran 
sulphate sodium induced colitis 
involving modulation of Th1/Th2 and 
Th17/Treg balance. Artif Cells Nanomed 
Biotechnol. 2019;47:757-766. DOI: 
10.1080/21691401.2019.1577877
[135] Won DP, Lee JS, Kwon DS, Lee KE, 
Shin WC, Hong EK. Immunostimulating 
activity by polysaccharides isolated from 
fruiting body of Inonotus obliquus. 
Molecules and Cells. 2011;31:165-173
[136] Bhardwaj N, Katyal P, Sharma AK. 
Suppression of inflammatory and 
allergic responses by pharmacologically 
potent fungus Ganoderma lucidum. 
Recent Patents on Inflammation & 
Allergy Drug Discovery. 2014;8:104-117. 
DOI: 10.2174/1872213x0866614061911
0657
[137] Ahmad MF. Ganoderma 
lucidum: Persuasive biologically 
active constituents and their health 
endorsement. Biomedicine & 
Pharmacotherapy. 2018;107:507-519. 
DOI: 10.1016/j.biopha.2018.08.036
[138] Sohretoglu D, Huang S. Ganoderma 
lucidum Polysaccharides as An Anti-
cancer Agent. Anti-Cancer Agents in 
Medicinal Chemistry. 2018;18:667-674. 
DOI: 10.2174/1871520617666171113121
246
[139] Xie, J.; Liu, Y.; Chen, B.; Zhang, 
G.; Ou, S.; Luo, J.; Peng, X. Ganoderma 
lucidum polysaccharide improves rat 
DSS-induced colitis by altering cecal 
microbiota and gene expression of 
colonic epithelial cells. Food Nutr Res. 
2019;63. doi: 10.29219/fnr.v63.1559.
[140] Chang CJ, Lin CS, Lu CC, Martel J, 
Ko YF, Ojcius DM, et al. Ganoderma 
lucidum reduces obesity in mice by 
modulating the composition of the gut 
microbiota. Nature Communications. 
2015;6:7489. DOI: 10.1038/ncomms8489
[141] Chen M, Xiao D, Liu W, Song Y, 
Zou B, Li L, et al. Intake of Ganoderma 
lucidum polysaccharides reverses 
the disturbed gut microbiota and 
metabolism in type 2 diabetic rats. 
International Journal of Biological 
Macromolecules. 2020a;155:890-902. 
DOI: 10.1016/j.ijbiomac.2019.11.047
[142] Chen, Y.; Wang, J.; Yu, L.; Xu, T.; 
Zhu, N. Microbiota and metabolome 
responses in the cecum and serum 
of broiler chickens fed with plant 
essential oils or virginiamycin.Sci 
Rep. 2020b; 10:5382. doi: 10.1038/
s41598-020-60135-x
[143] Hyun KW, Jeong SC, 
Lee DH, Park JS, Lee JS. Isolation and 
characterization of a novel platelet 
aggregation inhibitory peptide 
Alternative Medicine
40
from the medicinal mushroom. 
Inonotus obliquus. Peptides. Jun. 
2006;27:1173-1178. DOI: 10.1016/j.
peptides.2005.10.005
[144] Liu P, Xue J, Tong S, Dong W, 
Wu P. Structure characterization and 
Hypoglycaemic activities of two 
polysaccharides from Inonotus obliquus. 
Molecules. 2018a;23:1948. DOI: 10.3390/
molecules23081948
[145] Liu S, Song M, Yun W, Lee J, 
Lee C, Kwak W, et al. Effects of oral 
administration of different dosages 
of carvacrol essential oils on 
intestinal barrier function in broilers. 
J Anim Physiol Anim Nutr (Berl). 
2018b;102:1257-1265. DOI: 10.1111/
jpn.12944
[146] Kikuchi Y, Seta K, Ogawa Y, 
Takayama T, Nagata M, Taguchi T, et 
al. Chaga mushroom-induced oxalate 
nephropathy. Clinical Nephrology. 
2014;81:440-444. DOI: 10.5414/
CN107655
[147] Tao J, Feng KY. Experimental and 
clinical studies on inhibitory effect 
of Ganoderma lucidum on platelet 
aggregation. Journal of Tongji Medical 
University. 1990;10:240-243. DOI: 
10.1007/BF02887938
[148] Wang X, Zhao X, Li D, 
Lou YQ, Lin ZB, Zhang GL. Effects of 
Ganoderma lucidum polysaccharide on 
CYP2E1, CYP1A2 and CYP3A activities 
in BCG-immune hepatic injury in rats. 
Biological & Pharmaceutical Bulletin. 
Sep 2007;30(9):1702-1706. DOI: 
10.1248/bpb.30.1702
[149] Thumann TA, Pferschy-Wenzig EM, 
Moissl-Eichinger C, Bauer R. The 
role of gut microbiota for the activity 
of medicinal plants traditionally 
used in the European Union for 
gastrointestinal disorders. Journal of 
Ethnopharmacology. 2019;245:112153. 
DOI: 10.1016/j.jep.2019.112153
[150] Khoobani, M.; Hasheminezhad, S. 
H.; Javandel, F.; Nosrati, M.; Seidavi, A.; 
Kadim, I. T.; Laudadio, V.; Tufarelli, V. 
Effects of Dietary Chicory (Chicorium 
intybus L.) and Probiotic Blend as 
Natural Feed Additives on Performance 
Traits, Blood Biochemistry, and 
Gut Microbiota of Broiler Chickens. 
Antibiotics (Basel). 2019;9:5. 
doi:10.3390/antibiotics9010005.
[151] Fouré M, Dugardin C, Foligné B, 
Hance P, Cadalen T, Delcourt A, et al. 
Chicory roots for prebiotics and appetite 
regulation: A pilot study in mice. Journal 
of Agricultural and Food Chemistry. 
2018;66:6439-6449. DOI: 10.1021/acs.
jafc.8b01055
[152] Ismail IE, Abdelnour SA, Shehata SA, 
Abd El-Hack ME, El-Edel MA, Taha AE, 
et al. Effect of dietary Boswellia serrata 
resin on growth performance, 
blood biochemistry, and Cecal 
microbiota of growing rabbits. Front 
Vet Sci. 2019;6:471. DOI: 10.3389/
fvets.2019.00471
[153] Jeffery LE, Qureshi OS, Gardner D,  
Hou TZ, Briggs Z, Soskic B, et al. 
Vitamin D Antagonises the suppressive 
effect of inflammatory cytokines on 
CTLA-4 expression and regulatory 
function. PLoS One. 2015;10:e0131539. 
DOI: 10.1371/journal.pone.0131539
[154] Kannt, A.; Papada, E.; 
Kammermeier, C.; D’Auria, G.; 
Jiménez-Hernández, N.; Stephan, 
M.; Schwahn, U.; Madsen, A. N.; 
Østergaard, M. V.; Dedoussis, G.; 
Francino, M. P.; MAST4HEALTH 
consortium. Mastiha (Pistacia lentiscus) 
Improves Gut Microbiota Diversity, 
Hepatic Steatosis, and Disease Activity 
in a Biopsy-Confirmed Mouse Model of 
Advanced Non-Alcoholic Steatohepatitis 
and Fibrosis. Mol Nutr Food Res. 
2019;63:e1900927. doi:10.1002/
mnfr.201900927.
[155] Marcelino G, Hiane PA, Freitas KC, 
Santana LF, Pott A, Donadon JR, 
et al. Effects of olive oil and its minor 
41
Natural Compounds in the Modulation of the Intestinal Microbiota: Implications in Human…
DOI: http://dx.doi.org/10.5772/intechopen.94043
components on cardiovascular diseases, 
inflammation, and gut microbiota. 
Nutrients. 2019;11:1826. DOI: 10.3390/
nu11081826
[156] Vezza, T.; Rodríguez-Nogales, A.; 
Algieri, F.; Garrido-Mesa, J.; Romero, 
M.; Sánchez, M.; Toral, M.; Martín-
García, B.; Gómez-Caravaca, A. M.; 
Arráez-Román, D.; Segura-Carretero, 
A.; Micol, V.; García, F.; Utrilla, M. P.; 
Duarte, J.; Rodríguez-Cabezas, M. E.; 
Gálvez, J. The metabolic and vascular 
protective effects of olive (Olea europaea 
L.) leaf extract in diet-induced obesity 
in mice are related to the amelioration 
of gut microbiota dysbiosis and to 
its immunomodulatory properties. 
Pharmacol Res. 2019;150:104487. 
doi:10.1016/j.phrs.2019.104487.
[157] Rizzello F, Ricci C, Scandella M, 
Cavazza E, Giovanardi E, Valerii MC, 
et al. Dietary geraniol ameliorates 
intestinal dysbiosis and relieves 
symptoms in irritable bowel 
syndrome patients: A pilot study. 
BMC Complementary and Alternative 
Medicine. 2018;18:338. DOI: 10.1186/
s12906-018-2403-6
[158] Spisni, E.; Petrocelli, G.; Imbesi, 
V.; Spigarelli, R.; Azzinnari, D.; Donati 
Sarti, M.; Campieri, M.; Valerii, M.C. 
Antioxidant, Anti-Inflammatory, and 
Microbial-Modulating Activities of 
Essential Oils: Implications in Colonic 
Pathophysiology Int J Mol Sci. 2020; 21: 
4152. doi: 10.3390/ijms21114152
[159] Thapa, D.; Losa, R.; Zweifel, B.; 
Wallace, R.J. Sensitivity of pathogenic 
and commensal bacteria from 
the human colon to essential oils. 
Microbiology 2012, 158, 2870-2877. 
doi:10.1099/mic.0.061127-0
[160] Swamy MK, Akhtar MS, 
Sinniah UR. Antimicrobial properties 
of plant essential oils against human 
pathogens and their mode of action: 
An updated review. Evidence-based 
Complementary and Alternative 
Medicine. 2016;2016:3012462. DOI: 
10.1155/2016/3012462
[161] Tariq S, Wani S, Rasool W, 
Bhat MA, Prabhakar A, Shalla AH, 
et al. A comprehensive review of the 
antibacterial, antifungal and antiviral 
potential of essential oils and their 
chemical constituents against drug-
resistant microbial pathogens. Microbial 
Pathogenesis. 2019;134:103580. DOI: 
10.1016/j.micpath.2019.103580
[162] Solórzano-Santos F, 
Miranda-Novales MG. Essential oils 
from aromatic herbs as antimicrobial 
agents. Current Opinion in 
Biotechnology. 2012;23:136-141. DOI: 
10.1016/j.copbio.2011.08.005
[163] Altop A, Erener G, Duru ME, 
Isik K. Effects of essential oils from 
Liquidambar orientalis mill. Leaves on 
growth performance, carcass and some 
organ traits, some blood metabolites 
and intestinal microbiota in broilers. 
British Poultry Science. 2018;59:121-127. 
DOI: 10.1080/00071668.2017.1400657
[164] Park, J.H.; Kim, I.H. Effects of a 
protease and essential oils on growth 
performance, blood cell profiles, 
nutrient retention, ileal microbiota, 
excreta gas emission, and breast meat 
quality in broiler chicks.Poult Sci. 2018; 
97:2854-2860. doi: 10.3382/ps/pey151
[165] Ceppa F, Faccenda F, De Filippo C,  
Albanese D, Pindo M, Martelli R, 
et al. Influence of essential oils in diet 
and life-stage on gut microbiota and 
fillet quality of rainbow trout 
(Oncorhynchus mykiss). International 
Journal of Food Sciences and 
Nutrition. 2018;69:318-333. DOI: 
10.1080/09637486.2017.1370699
[166] Arzola-Alvarez, C.; Hume, 
M.E.; Anderson, R.C.; Latham, E.A.; 
Ruiz-Barrera, O.; Castillo-Castillo, Y.; 
Olivas-Palacios, A.L.; Felix-Portillo, 
M.; Armendariz-Rivas, R.L.; Arzola-
Rubio, A.; Ontiveros-Magadan, M.; 
Alternative Medicine
42
Bautista-Martínez, Y.; Salinas-Chavira, 
J. Influence of sodium chlorate, ferulic 
acid, and essential oils on Escherichia coli 
and porcine fecal microbiota. J Anim 
Sci. 2020; 98:skaa059. doi: 10.1093/jas/
skaa059
[167] Abouelezz K, Abou-Hadied M, 
Yuan J, Elokil AA, Wang G, Wang S, 
et al. Nutritional impacts of dietary 
oregano and Enviva essential oils on the 
performance, gut microbiota and blood 
biochemicals of growing ducks. Animal. 
2019;13:2216-2222. DOI: 10.1017/
S1751731119000508
[168] Lorenzi V, Muselli A,  
Bernardini AF, Berti L, Pagès JM, 
Amaral L, et al. Geraniol restores 
antibiotic activities against multidrug-
resistant isolates from gram-negative 
species. Antimicrobial Agents and 
Chemotherapy. 2009;53:2209-2211. 
DOI: 10.1128/AAC.00919-08
[169] De Fazio L, Spisni E, Cavazza E, 
Strillacci A, Candela M, Centanni M, 
et al. Dietary geraniol by oral or enema 
administration strongly reduces 
dysbiosis and systemic inflammation in 
dextran sulfate sodium-treated mice. 
Frontiers in Pharmacology. 2016;7:38. 
DOI: 10.3389/fphar.2016.00038
[170] Gill AO, Holley RA. Disruption of 
Escherichia coli, listeria monocytogenes 
and lactobacillus sakei cellular 
membranes by plant oil aromatics. 
International Journal of Food 
Microbiology. 2006;108:1-9. DOI: 
10.1016/j.ijfoodmicro.2005.10.009
[171] Cui H, Zhang C, Li C, Lin L. 
Antimicrobial mechanism of clove 
oil on listeria monocytogenes. Food 
Control. 2018;94:140-146. DOI: 
10.1016/j.foodcont.2018.07.007
[172] Wlodarska M, Willing B,  
Bravo D, Finlay BB. Phytonutrient  
diet supplementation promotes 
beneficial clostridia species and 
intestinal mucus secretion resulting in 
protection against enteric infection. 
Scientific Reports. 2015;5:9253. DOI: 
10.1038/srep09253
[173] Valdivieso-Ugarte M, 
Gomez-Llorente C, Plaza-Díaz J, 
Gil Á. Antimicrobial, antioxidant, 
and immunomodulatory properties 
of essential oils: A systematic review. 
Nutrients. 2019, E2786;11. DOI: 10.3390/
nu11112786
[174] Bayoub K, Baibai T, Mountassif D, 
Retmane A, Soukri A. Antibacterial 
activities of the crude ethanol extracts 
of medicinal plants against listeria 
monocytogenes and some other 
pathogenic strains. African Journal 
of Biotechnology. 2010;9:4251-4258 
https://doi.org/10.5897/AJB09.1393
[175] Senhaji O, Faid M, Kalalou I. 
Inactivation of Escherichia coli O157:H7 
by essential oil from cinnamomum 
zeylanicum. The Brazilian 
Journal of Infectious Diseases. 
2007;11:234-236. DOI: 10.1590/
s1413-86702007000200013
[176] Meades, G. Jr.; Henken, R.L.; 
Waldrop, G.L.; Rahman, M.M.; Gilman, 
S.D.; Kamatou, G.P.; Viljoen, A.M.; 
Gibbons, S. Constituents of cinnamon 
inhibit bacterial acetyl CoA carboxylase. 
Planta Med.2010,76, 1570-1575. 
doi:10.1055/s-0030-1249778.
[177] Unlu M, Ergene E, Unlu GV, 
Zeytinoglu HS, Vural N. Composition, 
antimicrobial activity and in vitro 
cytotoxicity of essential oil from 
cinnamomum zeylanicum blume 
(lauraceae). Food and Chemical 
Toxicology. 2010;48:3274-3280. DOI: 
10.1016/j.fct.2010.09.001
[178] Li AL, Ni WW, Zhang QM, 
Li Y, Zhang X, Wu HY, et al. Effect of 
cinnamon essential oil on gut microbiota 
in the mouse model of dextran sodium 
sulfate-induced colitis. Microbiology 
and Immunology. 2020;64:23-32. DOI: 
10.1111/1348-0421.12749
43
Natural Compounds in the Modulation of the Intestinal Microbiota: Implications in Human…
DOI: http://dx.doi.org/10.5772/intechopen.94043
[179] Kelly C, Gundogdu O,  
Pircalabioru G, Cean A, Scates P, 
Linton M, et al. The in vitro and in 
vivo effect of carvacrol in preventing 
campylobacter infection, colonization 
and in improving productivity of 
chicken broilers. Foodborne Pathogens 
and Disease. 2017;14:341-349. DOI: 
10.1089/fpd.2016.2265
[180] Li D, Wu, h.; Dou, H.; Guo L. 
Huang W. Microcapsule of sweet  
orange essential oil changes gut 
microbiota in diet-induced obese 
rats. Biochem Biophys Res Commun. 
2018;505:991-995. DOI: 10.1016/j.
bbrc.2018.10.035
[181] Dhakad AK, Pandey VV, 
Beg S, Rawat JM, Singh A. Biological, 
medicinal and toxicological significance 
of eucalyptus leaf essential oil: A review. 
Journal of the Science of Food and 
Agriculture. 2018;98:833-848. DOI: 
10.1002/jsfa.8600
[182] Kamatou GPP, Vermaak I, 
Viljoen AM, Lawrence BM. Menthol: A 
simple monoterpene with remarkable 
biological properties. Phytochemistry. 
2013;96:15-25. DOI: 10.1016/j.
phytochem.2013.08.005
[183] Qin, J.; Li, R.; Raes, J.; Arumugam, 
M.; Burgdorf, K.S.; Manichanh, C.; 
Nielsen, T.; Pons, N.; Levenez, F.; 
Yamada, T.; Mende, D.R.; Li, J.; Xu, J.; 
Li, S.; Li, D.; Cao, J.; Wang, B.; Liang, 
H.; Zheng, H.; Xie, Y.; Tap, J.; Lepage, 
P.; Bertalan, M.; Batto, J.; Hansen, T.; 
Paslier, D.L.; Linneberg, A.; Nielsen, 
H.B.; Pelletier, E.; Renault, P.; Sicheritz-
Ponten, T.; Turner, K.; Zhu, H.; Yu, C.; 
Li, S.; Jian, M.; Zhou, Y.; Li, Y.; Zhang, 
X.; Li, S.; Qin, N.; Yang, H.; Wang, 
J.; Brunak, S.; Doré, J.; Guarner, F.; 
Kristiansen, K.; Pedersen, O.; Parkhill, 
J.; Weissenbach, J.; Consortium, M.; 
Bork, P.; Ehrlich, S.D.; Wang, J. A 
human gut microbial gene catalogue 
established by metagenomic sequencing. 
Nature 2010,464, 59-65. doi:10.1038/
nature08821.
[184] Iliev, I.D.; Funari, V.A.; Taylor, 
K.D.; Nguyen, Q.; Reyes, C.N.; Strom, 
S.P.; Brown, J.; Becker, C.A.; Fleshner, 
P.R.; Dubinsky, M.; Rotter, J.I.; Wang, 
H.L.; McGovern, D.P.B.; Brown, G.D.; 
Underhill, D.M. Interactions between 
commensal fungi and the C-type 
lectin receptor Dectin-1 influence 
colitis. Science 2012; 336, 1314-1317. 
doi:10.1126/science.1221789
[185] Tong Y, Tang J. Candida  
albicans infection and intestinal 
immunity. Microbiological Research. 
2017;198:27-35. DOI: 10.1016/j.
micres.2017.02.002
[186] Botschuijver S, 
Roeselers G, Levin E, Jonkers DM, 
Welting O, Heinsbroek SEM, et al. 
Intestinal fungal dysbiosis associates 
with visceral hypersensitivity in patients 
with irritable bowel syndrome and rats. 
Gastroenterology. 2017;153:1026-1039. 
DOI: 10.1053/j.gastro.2017.06.004
[187] Sokol H, Leducq V, Aschard H, 
Pham H, Jegou S, Landman C, et al. 
Fungal microbiota dysbiosis in IBD. 
Gut. 2017;66:1039-1048. DOI: 10.1136/
gutjnl-2015-310746
[188] Iliev ID, Leonardi I. Fungal 
dysbiosis: Immunity and interactions 
at mucosal barriers. Nature Reviews. 
Immunology. 2017;17:635-646. DOI: 
10.1038/nri.2017.55
[189] Bona E, Cantamessa S, Pavan M, 
Novello G, Massa N, Rocchetti A, et 
al. Sensitivity of Candida albicans to 
essential oils: Are they an alternative to 
antifungal agents? Journal of Applied 
Microbiology. 2016;121:1530-1545. DOI: 
10.1189/jlb.0306164
[190] Gucwa K, Milewski S, Dymerski T, 
Szweda P. Investigation of the antifungal 
activity and mode of action of thymus 
vulgaris, citrus limonum, pelargonium 
graveolens, cinnamomum cassia, 
ocimum basilicum, and eugenia 
caryophyllus essential oils. Molecules. 
Alternative Medicine
44
2018;23:E1116. DOI: 10.1016/j.
ijfoodmicro.2005.10.009
[191] Shreaz S, Bhatia R, Khan N, 
Maurya IK, Ahmad SI, Muralidhar S, et 
al. Cinnamic aldehydes affect hydrolytic 
enzyme secretion and morphogenesis 
in oral Candida isolates. Microbial 
Pathogenesis. 2012;52:251-258. DOI: 
10.1016/j.micpath.2011.11.005
[192] Chee HY, Kim H, Lee MH. In vitro 
antifungal activity of limonene against 
Trichophyton rubrum. Mycobiology. 
2009;37:243-246. DOI: 10.4489/
MYCO.2009.37.3.243
[193] Thakre A, Zore G, 
Kodgire S, Kazi R, Mulange S, Patil R, et 
al. Limonene inhibits Candida albicans 
growth by inducing apoptosis. Medical 
Mycology. 2018;56:565-578. DOI: 
10.1093/mmy/myx074
[194] Stringaro, A.; Colone, M.; 
Angiolella, L. Antioxidant, antifungal, 
antibiofilm, and cytotoxic activities 
of Mentha spp. essential oils. 
Medicines(Basel).2018; 5: E112. 
doi:10.3390/medicines5040112.
[195] Botschuijver S, 
Welting O, Levin E, Maria-Ferreira D, 
Koch E, Montijin RC, et al. Reversal 
of visceral hypersensitivity in rat 
by Menthacarin®, a proprietary 
combination of essential oils from 
peppermint and caraway, coincides 
with mycobiome modulation. 
Neurogastroenterology and Motility. 
2018;30:e13299. DOI: 10.1111/
nmo.13299
[196] Pinto, E.; Pina-Vaz, C.; Salgueiro, 
L.; Gonçalves, M. J.; Costa-de-Oliveira, 
S.; Cavaleiro, C.; Palmeira, A.; 
Rodrigues, A.; Martinez-de-Oliveira, 
J. Antifungal activity of the essential 
oil of Thymus pulegioides on Candida, 
Aspergillus and dermatophyte species. 
J Med Microbiol. 2006, 55, 1367-1373. 
doi:10.1099/jmm.0.46443-0.
[197] Marchese A, Barbieri R, Coppo E, 
Orhan IE, Daglia M, Nabavi SF, et al. 
Antimicrobial activity of eugenol and 
essential oils containing eugenol: A 
mechanistic viewpoint. Critical Reviews 
in Microbiology. 2017;43:668-689. DOI: 
10.1080/1040841X.2017.1295225
[198] Rajkowska K, Nowicka-Krawczyk P, 
Kunicka-Styczynska A. Effect of 
clove and thyme essential oils on 
Candida biofilm formation and 
the oil distribution in yeast cells. 
Molecules. 2019;24:1-12. DOI: 10.3390/
molecules24101954
[199] Braga P, Dal Sasso M, Culici M, 
Alfieri M. Eugenol and thymol, alone or 
in combination, induce morphological 
alterations in the envelope of Candida 
albicans. Fitoterapia. 2007;78:396-400. 
DOI: 10.1016/j.fitote.2007.02.022
[200] Schnitzler P. Essential oils for 
the treatment of herpes simplex virus 
infections. Chemotherapy. 2019;64:1-7. 
DOI: 10.1159/000501062
[201] Seo SU, Kweon MN. Virome-
host interactions in intestinal health 
and disease. Current Opinion in 
Virology. 2019;37:63-71. DOI: 10.1016/j.
coviro.2019.06.003
[202] Reyes A, Haynes M, Hanson N, 
Angly FE, Heath AC, Rohwer F, et al. 
Viruses in the faecal microbiota of 
monozygotic twins and their mothers. 
Nature. 2010;466:334-338. DOI: 
10.1038/nature09199
[203] Kim MS, Park EJ, Roh SW, 
Bae JW. Diversity and abundance of 
single-stranded DNA viruses in human 
feces. Applied and Environmental 
Microbiology. 2011;77:8062-8070. DOI: 
10.1128/AEM.06331-11
